CA2478515C - Pharmaceutical preparation containing oxycodone and naloxone - Google Patents
Pharmaceutical preparation containing oxycodone and naloxone Download PDFInfo
- Publication number
- CA2478515C CA2478515C CA2478515A CA2478515A CA2478515C CA 2478515 C CA2478515 C CA 2478515C CA 2478515 A CA2478515 A CA 2478515A CA 2478515 A CA2478515 A CA 2478515A CA 2478515 C CA2478515 C CA 2478515C
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- oral pharmaceutical
- pharmaceutical preparation
- oxycodone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- MUFZPFIKPTVIIG-UHFFFAOYSA-N CCC(CCC1)C1C1CCC(C)CC1 Chemical compound CCC(CCC1)C1C1CCC(C)CC1 MUFZPFIKPTVIIG-UHFFFAOYSA-N 0.000 description 1
- AZIMTRHQTPSRKY-UHFFFAOYSA-N CCCCC1CC(C)CC1 Chemical compound CCCCC1CC(C)CC1 AZIMTRHQTPSRKY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
The invention concerns a storage stable pharmaceutical preparation comprising oxycodone and naloxone for use in pain therapy, with the active compounds being released from the preparation in a sustained, invariant and independent manner.
Description
Pharmaceutical preparation containing oxycodone and naloxone The invention concerns a storage-stable pharmaceutical preparation comprising oxycodone and naloxone.
The treatment of severe pain which results from diseases such as cancer, rheumatism and arthritis is central to the treatment of these diseases. The range of pain felt by tumor patients comprises pain of the periosteum and of the bone itself, as well as visceral pain and pain in soft tissues. All such pain forms render the daily life of patients intolerable and often lead to depressive states. Successful pain therapy resulting in a lasting improvement of quality of life for the patients is therefore equally important to the success of a comprehensive therapy, as is the treatment of the actual causes of the disease.
Regarding the importance of a successful pain therapy, the World Health Organization (WHO) has developed a 4-step model for the treatment of patients with tumor pain. This model has proven to be effective in daily routine practice and can be extended to patients suffering from chronic pain or pain forms which result from diseases other than cancer. Depending on the intensity, quality and localization of pain, four steps are distinguished during this therapy, with each next step being indicated if the effect of the pain relief agent used until then is no longer sufficient (Ebell, H. J.; Bayer A. (Ed.): Die Schmerzbehandlung von Tumorpatienten, Thieme 1994 (Supportive Mal3nahmen in der Onkologie, Band 3) and Zech, D.; Grond, S.;
Lynch, J.; Hertel, D.; Lehmann, I~.: Validation of World Health Organisation Guidelines for Cancer Pain Relief: a 10-year prospective study, Pain (1995), 63, 65-76).
According to this 4-step model of the WHO, opioid analgesics take a central role in treating pain. The group of opioid analgesics comprises, besides morphine which represents the prototype of these pharmaceutically active agents, also oxycodone, hydromorphone, nicomorphine, dihydrocodeine, diamorphine, papaveretum, codeine, ethylmorphine, phenylpiperidine and derivatives thereof; methadone, dextropropoxyphene, buprenorphine, pentazocine, tilidine, tramadol and hydrocodone. The ATC-Classification (Anatomical Therapeutic Chemical S Classification) of the WHO indicates whether the pharmaceutically active agent represents an opiod analgesic, or not. The pronounced pain-relieving effect of opioid analgesics is due to the imitation of the effect of endogenous, morphine-like acting substances ("endogenous opioids"), whose physiological function is to control the reception and processing of pain stimuli.
Opioids repress the propagation of pain stimuli. Besides the immediate inhibition of neuronal excitatory signal transduction in the spinal cord caused by opioids, an activation of such nerve tracts is relevant, which project form the brainstem into the spinal cord. This activation results in an inhibition of pain propagation in the spinal cord. Moreover, opioids limit the pain reception of the thalamus and by affecting the limbic system they influence the affective pain evaluation.
Opioid receptors are found at different sites in the body. Receptors of the intestine and brain are of particular importance for pain therapy by opioids, especially as their occupation results in different side effects.
Opioid analgesics are considered to be strong agonists if they bind with high affinity to opioid receptors and induce a strong inhibition of pain reception.
Substances that also bind with high affinity to opioid receptors, but that do not provoke a reduction of pain reception and which thereby counteract the opioid agonists, are designated as antagonists. Depending on the binding behaviour and the induced activity, opioids can be classified as pure agonists, mixed agonists/antagonists and pure antagonists.
Pure antagonists comprise, for example, naltrexone, naloxone, nalmefene, nalorphine, nalbuphine, naloxoneazinen, methylnaltrexone, ketylcyclazocine, norbinaltorphimine, naltrindol, 6-13-naloxol and 6-13-naltrexol (Forth W.;
Henschler, D.; Rummel W.; Starke, K.: Allgemeine and Spezielle Pharmakologie and Toxikologie, 7. Auflage, 1996, Spektrum Akademischer Verlag, Heidelberg Berlin Oxford).
Due to their good analgesic efficiency compounds such as oxycodone, tilidine, buprenorphine and pentazocine, have been used in the form of medicaments for pain therapy. Medicaments such as Oxigesic~ (wherein oxycodone is the analgesic active compound) and Valoron~ (wherein tilidine is the analgesic active compound ) have proven valuable for pain therapy.
However, use of opioid analgesics far pain therapy might go along with undesirable side effects. Thus, long-term use of opioid analgesics can lead to psychological and physical dependence.
Especially the physical dependence of patients suffering from pain to opioid analgesics leads to the development of tolerance, meaning that upon extended intake, increasingly higher doses of the pain relieving agent have to be taken by the patient, in order to experience pain relief. The euphoregenic effect of opioid analgesics often leads to the abuse of pain relievers. Drug abuse and psychological dependence are a common phenomenon, especially among teenagers. These dangerous effects are especially caused by the substances with strong analgesic capacity, and can range from undesired habituation to fully developed addiction. However, these substances are legitimately used for medical purposes and medicine cannot do without them.
Besides the mentioned disadvantages, the use of potent opioid analgesics for pain therapy often also lead to undesirable side effects, such as obstipation, breath depression, sickness and sedation. Less frequently, the urge or the disability to pass water are observed. Different attempts have been made to counteract the habituation processes and the other side effects occurring during pain therapy. This can be done, e.g. by traditional treatment methods. In the case of drug addiction this might be a drug withdrawal treatment, and in the case of obstipation, this might be done by administration of laxatives.
Other attempts aim at minimizing the addictive and habituation forming potential of opioid analgesics, as well as their other side effects by the administration of antagonists which counteract the opioid analgesic. Such antagonists might be naltrexone or naloxone.
There have been numerous proposals and suggestions, how the application of the aforementioned active compounds could be used~to avoid undesired habituation and dependence, or even addiction.
US Patent Nos. 3,773,955 and 3,966,940 suggested to formulate analgesics in combination with naloxone, in order to prevent dependence-promoting effects such as euphoria and the like, upon parenteral application. The avoidance of side effects such as obstipation has not been addressed.
To limit the parenteral abuse of oral application forms, US Patent No.
4,457,933 suggested the combination of morphine with naloxone in defined ranges. The avoidance of side effects such as obstipation has also not been mentioned.
US Patent No. 4,582,835 describes, again in order to avoid abuse, a preparation comprising a combination of buprenorphine and naloxone , that is to be administered either parenterally or sublingually.
European application EP 0 352 361 A1 concerns the treatment of obstipation during pain therapy by the oral application of an opioid analgesic and one antagonist, with the antagonist being a pro-drug form of either naltrexone or naloxone.
Avoidance of abuse of the opioid analgesic is not an issue in this application.
German patent application DE 43 25 465 A1 also concerns the treatment of obstipation during pain therapy using a preparation which comprises an opioid analgesic and an antagonist. The characterizing feature of this disclosure is that the antagonist which can be naloxone, has to be present in higher amounts than the opioid analgesic which is preferably morphine. This is to ensure that the antagonist unfolds its anti-obstipation effect without reducing the analgesic activity of the agonist. The avoidance of abuse.of the opioid analgesic is not an issue in this application.
In order to avoid side effects such as obstipation and breath depression during pain therapy, preparations have been introduced on the market which can be taken orally and comprise an opioid analgesic and the opioid antagonist, naloxone. The medicament Talwin~ of Windrop/Sterling comprises pentazocine and naloxone. The medicament Valoron~ of Godeke comprises a tilidine-naloxone combination.
Besides the potent analgesic effect, the reduction of addictive potential and the avoidance of side effects, medicaments usable for a successful pain therapy should provide for additional characteristics.
Generally, medicaments have to be formulated in a way that the active compounds are stable as long as possible, under standard storage conditions. Medicaments have also to be formulated in a way that the intended release profiles of the active compounds do not change upon long-term storage.
Additionally, (also in the case of agonist/antagonist-combinations) the release profile of each single active compound should be selectable as required. The measures applied in order to achieve this should not hamper or even prevent that the release profiles of additional active compounds (e.g. in the case of combinations of different active compounds) can be chosen as required. Consequently, there should be no mutual dependency of the release profiles.
Medicaments suitable for pain therapy should either contain the active compounds in such amounts or be formulated in such ways hat they have to be taken by the patients only rarely. The easier the' application scheme for a pain reliever is, and the more evident it is for the patient why and how often he should take which tablet, the more exactly he will adhere to the physician's orders. The necessity to take the pain reliever only infrequently, will result in a high willingness of the patient to take the pain reliever (compliance).
Through the use of so called sustained-release formulations, i.e. formulations of medicaments from which the active compounds are released over an extended period of time, it has been tried to lower the frequency by which pain relieving medicaments have to be taken, and thereby to increase the compliance of patients. Such sustained-release formulations also make sense in that the sustained release of an opioid analgesic reduces the addictive potential of this active compound.
This is due to the fact that the addictive potential of an active compound is not defined by the compound itself, but rather by the way it is administered and the pharmaco-dynamics resulting therefrom. Besides the psychotropic effect of an _ 'J _ opioid, the rate by which the brain encounters an opioid, is more decisive criterion for the risk of dependency than the active compound itself (Nolte, T.: STI~-Zeitschrift fiir angewandte Schmerztherapie, 2001, Vol. 2).
The medicament Oxigesic~ of Purdue is a preparation from which the opioid analgesic oxycodone is released in a sustained manner. Due to this formulation, the frequency by which the medicament has to be taken as well as the addictive potential is lowered, however the side effects remain and the danger of developing addiction cannot be excluded, as Oxigesic~ does not contain opioid-antagonists.
According to the already mentioned European patent application EP 0 352 361 A, neither the opioid analgesic nor the antagonist are formulated to be released in a sustained manner. Accordingly, the time period~during which such preparations are effective is limited and preparations have to be taken multiple times per day.
The desired compliance of the patient is not achieved. This application also does not disclose the advantages of formulations of preparations that are characterized by a time-stable and independent release of the active compounds. The storage stability of such preparations is also not addressed by this disclosure.
German patent application DE 43 25 465 A1 discloses formulations according to which obstipation occurring during pain therapy is prevented by the sustained release of the opioid agonist while the antagonist, which is present in excess must not be released in a sustained manner. Due to the high First-Pass-Effect of naloxone, comparably large amounts of this compound have therefore to be used. This application discloses neither the advantages nor the formulations of preparations, which are characterized by time-stable and independent release of the active compounds. The storage stability of such preparations is also not an issue of this _g_ disclosure. A doctor using preparations according to this disclosure has therefore to carry out extensive titration experiments each time he wants to increase the dosage.
The company Godeke offers, under the trademark Valoron~, a pain reliever that comprises a tilidine-naloxone-combination. According to the product literature, a formulation is used from which both active compounds are released in a sustained manner. The matrix used comprises a relevant part of water-swellable material (HPMC) and has therefore to be considered as a swellable (and possibly partially erosive) diffusion matrix. A disadvantage of this known formulation is that tilidine and naloxone, given identical mass ratios but different absolute amounts, show different release profiles. The release rates of the agonist and the antagonist axe not independent from each other, which is probably due to the sustained release formu-lation used. Accordingly, it is necessary for the physician to carry out extensive titration experiments for each individual patient if he wants to increase the dosage even though he does not change the mass ratio of tilidine:naloxone, as he cannot assume that the release profiles of both components will remain constant. The range of therapeutically usable amounts of the analgesic that are available to the doctor is therefore limited.
It is one of the objectives of the present invention to provide a pharmaceutical preparation for pain therapy that, given a high analgesic activity, is characterized by a reduced abuse potential and reduced side effects, said preparation also being characterized by a reduced administration frequency and therefore providing increased compliance, as well as the ability for individual adaptation of the dosage for each patient. A further objective of the present invention is to provide formulations for pharmaceutical preparations usable in pain therapy that make sure that the active compounds of said pharmaceutical preparations are stable over a long storage time, and that the release of the active compounds remain reproducibly invariant and independent from each other even after long-term storage.
The feature combination of the independent claim serves to attain these, and further objectives which can be noted from the ensuing description of the invention.
Preferred embodiments of the invention are defined in the subclaims.
According to the invention, the objectives are attained by providing a storage-stable pharmaceutical preparation comprising oxycodone and naloxone wherein said preparation is formulated such that the active compounds are released in a sustained, invariant and independent manner.
By the combination of oxycodone (in:awanalgesically effective amounts and naloxone it is.ensured that preparations according to the invention show an efficient analgesic activity and that at the same time, common side effects such as obstipation, breath depression and development of addiction are suppressed, or at least significantly reduced. The matrix formulation, which is stable over extended periods of time, ensures permanently that agonist as well as antagonist are always released in predetermined percentages and that their release rates do not influence each other.
Thereby, abuse of the medicament, which requires that the oxycodone can selectively be extracted from the formulation, is prevented. The formulation according to the invention disables selective extraction of the agonist from the preparation without the corresponding amount of the antagonist, independent of the absolute and relative amounts of agonist and antagonist chosen.
Moreover, the formulation of a medicament according to the invention ensures that, given identical relative amounts, the active compounds show equal release profiles, independent of the absolute amount present. Such an independent release behaviour provides a wide range of useable absolute amounts of the analgesic active substance to the physician, given that the optimal agonist/antagonist ratio is known.
Thus, it is possible to comfortably adjust the dosage for each individual patient, either by a step-wise dosage increase or, if necessary, a step-wise dosage reduction. This ability to adjust the dosage for the individual patient is extremely useful from a medical point of view.
The characterizing features of the present invention, which comprise the sustained, invariant and independent release of the active compounds ensure additionally that pharmaceutical preparations produced according to the invention are characterized by a low administration frequency, so that high patient compliance is achieved.
Furthermore, preparations according to the invention allow the doctor to adjust the dosage for individual patients. Preparations according to the invention.
enable use:
over a broad range with respect to the useable absolute amounts of the active .
compounds and ensure that the active compounds, even after long-term storage, become effective with equal release profiles.
According to the present invention, sustained release of active compounds means that pharmaceutically active substances are released from a medicament over a longer period of time than they are from known formulations for immediate release.
Preferably, the release takes place over a time period of two to twenty four hours, of two to twenty hours, especially preferred over a time period of two to sixteen hours or two to twelve hours, with the specifications satisfying the legal and regulating requirements.
According to the invention, formulations of medicaments that ensure such a sustained release of the active compounds from the preparation, are designated as retard formulations, as sustained release formulations or as prolonged release formulations. In the context of the instant invention, "sustained release"
does not mean that the active compounds are released from the formulation or the medicament in a pH-dependent manner. According to the invention, the release of the active compounds rather occurs in a pH-independent manner. According to the invention, the term "sustained release" refers to the release of active compounds from a medicament over an extended period of time. It does not imply the controlled release at a defined place; therefore, it does not mean that the active compounds are either released only in the stomach, or only in the intestine. (Of course, such a release at a defined place could individually be achieved by, e.g., enteric coating of the medicament. However, this presently seems not to be advantageous.) According to the invention, "independent release" means that, given the presence of at least two active compounds, a change of the absolute amount of one compound does not influence the release profiles of the other compounds so that the release profiles of the other compounds are not changed. For formulations according to the invention such an independent release behaviour is independent of the pH
value, for which the release is measured, or of the production process. The pH
independency particularly applies to the acidic range, i.e. for pH values < 7. The release profile (or release behaviour) is defined as the change of the release of the active compound from the formulation with time, with the amount of each active compound released provided in percents of the total amount of the active compound. The release profile is determined by known tests.
Specifically, this means that for example the release profile of oxycodone, as it is observed for an oxycodone/naloxone-combination with 12 milligrams oxycodone and 4 milligrams naloxone, does not change, if a corresponding preparation with the same formulation contains 12 milligrams oxycodone, but 6 milligrams naloxone.
The independent release feature preferably refers to the situation where preparations of substantially equal composition are compared for the release profile.
Preparations of substantially equal composition have different amounts of the active compounds but are otherwise basically the same with respect the components of the composition which essentially influence the release behaviour.
If e.g. the above-mentioned preparations are compared (with the first preparation comprising 12 mg oxycodone and 4 mg naloxone and the second preparation comprising 12 mg oxycodone and 6 mg naloxone) both prepaxations, provided that they have the same total weight, will provide for the same release profile for oxycodone and naloxone if the difference in the naloxone amount is replaced by a component in the formulation that typically does not influence the release behaviour.
As shown in the Example section, the difference in the amount of naloxone~ my be replaced by a typical pharmaceutically inert filler such as lactose without changing the release profiles.
The person skilled in the art is well aware that if the amount of the active compound in which two preparations differ is replaced by a substance that is essential for the release behaviour of the formulation, such as ethylcellulose or a fatty alcohol, differences in the release behaviour may occur. Thus, the independent release feature preferably applies to formulations that have different amounts of the active compounds but are otherwise identical or at least highly similar with respect to the components that essentially influence the release behaviour (given that formulations of the same total weight are compaxed).
According to the invention, "invariant release behaviour" or "invariant release profile" is defined so that the percentage of the absolute amount of each active compound released per time unit does not significantly change and remains sufficiently constant (and thus does not substantially change) if absolute amounts are changed. Sufficiently constant percentages mean that the percentage released per time unit deviates from a mean value by not more than 20%, preferably by not more than 15% and especially preferably by not more than 10%. The mean value is calculated from six measurements of the release profile. Of course, the amount released per time unit has to satisfy the legal and regulatory requirements.
Specifically, this means for example that given an oxycodone/naloxone combination of 12 mg oxycodone and 4 mg naloxone, during the first 4 hours 25% oxycodone and 20% naloxone axe released. If the oxycodone/naloxone combination instead contains 24 mg oxycodone and 8 mg naloxone, during the first 4 hours also 25% oxycodone and 20% naloxone will be released. In both cases the deviation will not be more than.
20% from the mean value (which in this case is 25°f° oxycodone and 20% naloxone).
As outlined for the independent release behaviour, the invariant release feature also preferably refers to a situation where preparations of substantially equal composition are compared. Such preparation differ with respect to the amount of the active compounds, but are of the same or at least highly similar composition with respect to the release-influencing components of the preparation. Typically, the difference in the amount of an active compound will be replaced by the amount of a pharma-ceutical inert excipient which does not substantially influence the release behaviour of the preparation. Such a pharmaceutical excipient may be lactose, which is a typical filler in pharmaceutical preparations. The person skilled in the art is well aware that the invariant release feature may not apply to preparations where the difference in the amount of an active compound is replaced by substances that are known to essentially influence the release behaviour of the preparation, such as ethylcellulose or fatty alcohols.
In the Example section it is set out that if one preparation comprises 20 mg oxycodone and 1 mg naloxone or 20 mg oxycodone and 10 mg naloxone, with the difference in naloxone being replaced by lactose, that the two preparations of identical weight provide for the same release profiles, so that they exhibit a sustained, invariant and independent release behaviour.
According to the invention "storage stable" or "storage stability" means that upon storage under standard conditions (at least two years at room temperature and usual humidity) the amounts of the active compounds of a medicament formulation do not deviate from the initial amounts by more than the values given in the specification or the guidelines of the common Pharmacopoeias. According to the invention, storage stability also means. that a preparation produced according to the invention can be stored under standard conditions (60%~relative humidity, 25°C) as it is required for admission to the market.
According to the invention, "storage stable" or "time stable" also means that after storage under standard conditions the active compounds show release profiles as they would upon immediate use without storage. According to the invention, the admissible fluctuations with respect to the release profile are characterized in that the amount released per time unit fluctuates by no more than 20%, preferably no more than 15% and especially preferably no more than 10 %, with respect to a mean value.
The mean value is calculated from six measurements of the release profile.
Preferably, the release of the active compounds from a sustained release formulation is determined by the Basket Method according to USP at pH 1.2 or pH 6.5 with HPLC.
Storage stability is preferably determined by the Basket Method according to USP at pH 1.2 with HPLC.
According to the invention, a "non-swellable" or "substantially non-swellable"
diffusion matrix is a matrix formulation for which the release of the active compounds is not influenced (or at least not to a relevant degree) by swelling of the matrix (particularly in the physiological fluids of the relevant target sites in the patient's body).
According to the invention, the term "substantially non-swellable" diffusion matrix also refers to a matrix whose volume will increase by approximately 300%, preferably by approximately 200%, more preferably by approximately 100%, by approximately 75% or by approximately 50%, even more preferably by approximately 30% or by approximately 20% and most preferably by approximately 15%, by approximately 10%, by approximately 5% or by approximately 1% in aqueous solutions (and particularly in the physiological fluids of the relevant target sites in the patient's body).
In the context of the present invention, "agonist" or "analgesic" always refers to oxycodone. In the context of the present invention "antagonist" always refers to naloxone.
Preparations produced according to the invention can be applied orally, nasally, rectally and/or by inhalation for use in pain therapy. According to the invention, parenteral application is not envisaged. Especially preferred is a formulation for oral application.
Even though this might not be expressly stated, the term "agonist" or "antagonist"
always comprises pharmaceutical acceptable and equally acting derivatives, salts and the like. If, for example, oxycodone or naloxone is mentioned, this also comprises, besides the free base, their hydrochloride, sulfate, bisulfate, tatrate, nitrate, citrate, bitratrate, phosphate, malate, maleate, hydrobromide, hydrojodide, fumarate, succinate and the like.
According to the invention, agonists and antagonists are formulated in a way that they are released from the resulting pharmaceutical preparation in a sustained, independent and invariant manner. This does not mean that the antagonist is in excess compared to the agonist. On the contrary, it is preferred that in formulations comprising an agonist/antagonist combination, that show a release profile in accordance with the invention, the agonist is in excess compared to the antagonist.
The excess of the agonist is defined based on the amount of the unit dosage of the antagonist present in the combination preparation. The extent of the excess of the opioid agonist is usually given in terms of the weight ratio of agonist to antagonist.
In the case of oxycodone and naloxone, preferred weight ratios of agonist to antagonist lie within a weight ratio range of 25:1 at maximum, especially preferred are the weight ratio ranges 15:1, 10:1, 5:1, 4:1, 3:1, 2:1 and 1:1.
The absolute amounts of agonist and antagonist to be used depend on the choice of the active compounds. According to the invention, care has to be taken that agonist and antagonist are released from the pharmaceutical preparation that has been formulated for sustained release, only in an independent and invariant manner.
If oxycodone and naloxone are used for a combination preparation, preferably between 10 and 150 mg, especially preferably between 10 and 80 mg of oxycodone (typical amounts for use) and preferably between 1 and 50 mg naloxone per unit dosage are used.
In other preferred embodiments of the invention, the preparations may comprise between 5 and 50 mg of oxycodone, between 10 and 40 mg of oxycodone, between and 30 mg of oxycodone or approximately 20 mg of oxycodone. Preferred embodiments of the invention may also comprise preparations with between 1 and 10 mg naloxone, 1 and 30 mg naloxone, 1 and 20 mg naloxone or between 1 and 10 mg naloxone per unit dosage.
According to the invention, the ratio between oxycodone and naloxone has to be chosen in such a way that release profiles for both active substances in accordance with the invention are guaranteed and that the agonist can display its analgesic effect while the amount of the antagonist is chosen in such a way that habituation-or addiction-promoting effects and side effects of the agonist are reduced or abolished, without (substantially) affecting the analgesic effect of the agonist.
According to the invention, development of habituation and addiction as well as obstipation and breath depression are to be considered as side effects of analgesically effective opioid agonists.
According to the invention, generally common formulations can be used, given that these formulations ensure that the active compounds are released from the preparation in a sustained, independent and invariant manner. According to the invention, those formulations have to be chosen such that the active compounds are storage stable.
Matrix-based retardation formulations may preferably be used as formulations that provide a release of agonist and antagonist in accordance with the invention.
According to the invention, especially preferred are formulations based on a substantially non-swellable diffusion matrix. At the moment, formulations with an erosive matrix or a swellable diffusion matrix are not preferred.
According to the invention, the matrix that provides the sustained release of the active compounds, has to be chosen in such a way that the release of the active compounds occurs in a sustained, independent and invariant manner. Preferably such matrices comprise polymers based on ethylcellulose, with ethylcellulose being an especially preferred polymer. Specifically preferred are matrices comprising polymers as they are available on the market under the trademark Surelease~.
Particularly preferred is 'the use of Surelease~E-7-7050 Formulations with a release behaviour according to the invention comprise particularly matrices that comprise ethylcellulose and at least one fatty alcohol as the components that essentially influence the release characteristics of the matrix. The amounts of ethylcellulose and the at least one fatty alcohol may significantly vary so that preparations with different release profiles may be achieved. Even though the inventive preparations usually will comprise both of the afore-mentioned components, in some cases it may be preferred that the preparations comprise only ethylcellulose or the fatty alcohol(s) as the release determining components.
Matrices based on polymethacrylate (as, e.g. Eudragit~RS30D and Eudragit~RL30D) or matrices which comprise relevant amounts of water-swellable material, especially of hydroxyalkyl cellulose derivates such as HPMC, are presently preferably avoided according to the invention.
Matrices that are in accordance with the invention can be used to produce preparations that release active compounds in a sustained, independent and invariant manner and that release equal amounts of the active compounds per time unit.
Specifically, this means that in the case of a oxycodone/naloxone combination containing 12 mg oxycodone and 4 mg naloxone, 25% oxycodone and 25% naloxone are released within the first 4 hours. Correspondingly, in the case of a oxycodone/naloxone combination containing 24 mg oxycodone and 8 mg naloxone, 25% oxycodone and 25% naloxone are released during the first 4 hours, with the deviation in both cases being no more than 20% of the mean value (which in this case is 25% oxycodone or naloxone).
Such an equal release behaviour for both active compounds may be desirable for medical aspects.
A preferred embodiment of the invention relates to preparations that release 1 % to 40%, preferably 5% to 35%, more preferably between 10% and 30% and even more preferably between 15% and 25% of oxycodone and/or naloxone after 15 minutes.
In other preferred embodiments of the invention, 15% to 20%, 20% to 25%, approximately 15%, approximately 20% or approximately 25% of oxycodone and/or naloxone are released after 15 minutes.
Another preferred embodiment of the invention relates to preparations that release between 25% to 65%, preferably between 30% to 60%, more preferably between 35% to 55% and even more preferably between 40% to 50% of oxycodone and/or naloxone after one hour. Preferred embodiments of the invention also relate to preparations that release between 40% to 45%, 45% to 50%, approximately 40%, approximately 45% or approximately 50% of oxycodone and/or naloxone after one hour.
Yet another preferred embodiment of the invention relates to preparations that release between 40% to 80%, preferably between 45% to 75%, more preferably between 45% to 70% and even more preferably between 45% to 50%, 50% to 55%, 55% to 60%, 60% to 65% or 65% to 70% of oxycodone and/or naloxone after 2 hours. Preferred embodiments also comprise preparations that release approximately 45%, approximately 50%, approximately 55%, approximately 60%, approximately65% or approximately 70% of oxycodone and/or naloxone after 2 hours.
One preferred embodiment of the invention relates to preparations that release 70%
to 100%, preferably between 75% to 95%, more preferably between 80% to 95%, and even more preferably between 80% and 90% of oxycodone and/or naloxone after 4 hours. Preferred embodiments of the invention also relate to preparations that release between 80% to 85%, 85% to 90%, approximately 80%, approximately 85%
or approximately 90% of oxcodone and/or naloxone after 4 hours.
One preferred embodiment of the invention also relates to preparations that release between 70% to 100%, preferably between 75% to 100%, more preferably between 80% to 95% and even more preferably between 80% to 85%, between 85% to 90%
or between 90% to 95% of oxycodone and/or naloxone after 7 hours. Preferred embodiments of the invention also relate to preparations that release approximately 80%, approximately 85%, approximately 90% or approximately 95% of oxycodone and/or naloxone after 7 hours.
Yet another preferred embodiment of the invention relates to preparations that release between 85% to 100%, preferably between 90% to 100%, more preferably between 95% to 100% and even more preferably approximately 95% or 100% of oxycodone and/or naloxone after 12 hours.
According to the invention, formulations that provide a release of the active compounds in accordance with the invention may comprise, besides the matrix forming polymers, fillers and additional substances, such as granulating aids, lubricants, dyes, flowing agents and plasticizers.
Lactose, glucose or saccharose, starches and their hydrolysates, microcrystalline cellulose, cellatose, sugar alcohols such as sorbitol or mannitol, polysoluble calcium salts like calciumhydrogenphosphate, dicalcium- or tricalciumphosphat may be used as fillers.
Povidone may be used as granulating aid.
Highly-disperse silica (Aerosil~), talcum, corn starch, magnesium oxide and magnesium- or calcium stearate may preferably be used as flowing agents or lubricants.
Magnesium stearate and/or calcium stearate can preferably be used as lubricants.
Fatty acids like stearic acid, or fats like hydrated castor oil can also preferably be used.
Polyethylene glycols and fatty alcohols like cetyl and/or stearyl alcohol and/
or cetostearyl alcohol can also be used as additional substances that influence retardation.
_ 22 _ If fillers and additional substances such as dyes and the mentioned lubricants, flowing agents and plasticizers are used, care has to be taken that according to the invention only such combinations together with the matrix forming substance and/or the matrix forming substances are used, which ensure release profiles of the active compounds in accordance with the invention.
All these additional components of the formulations will be chosen in such a way that the release matrix receives the character of a substantially non-water-or non-buffer-swellable and non-erosive diffusion matrix.
According to the invention, a formulation is especially preferred that comprises ethylcellulose or Surelease~ E-7-7050 as a matrix-building substance, stearyl alcohol as fatty alcohol, magnesium stearate as lubricant, lactose as filler and povidone as a granulating aid.
Preparations in accordance with the invention can be produced as all common application forms which, on principle, are suitable for retardation formulations and which ensure that the active compounds are released in a manner in accordance with the invention. Especially suitable are tablets, mufti-layer tablets and capsules.
Additional application forms like granules or powders can be used, with only those applications forms being admissible that provide a sufficient retardation and a release behaviour in accordance with the invention.
Pharmaceutical preparations may also comprise film coatings. However, it has to be ensured that the film coatings do not negatively influence the release properties of the active compounds from the matrix and the storage stability of the active compounds within the matrix. Such film coatings may be colored or may comprise a initial dosage of the active compounds if required. The active compounds of this initial dosage will be immediately released so that the therapeutically effective blood plasma level is reached very quickly.
Pharmaceutical preparations or preliminary stages thereof which are in accordance with the invention can be produced by build-up or break-down granulation. A
preferred embodiment is the production by spray granulation with subsequent drying of the granules. Another preferred embodiment is the production of granules by build-up granulation in a drum or on a granulating disk. The granules may then be pressed into e.g. tablets using appropriate additional substances and procedures.
The person skilled in the art is familiar with granulating technology as applied to pharmaceutical technology. The embodiment examples (see below) disclose specific embodiments of the invention. ~ I-Iowever, it is well within the scope of the person skilled in the art to adapt the parameters of the process in order to achieve specific purposes.
Production of pharmaceutical preparations or preliminary stages thereof, which are in accordance with the invention, by extrusion technology is especially advantageous.
In one preferred embodiment, pharmaceutical preparations or preliminary stages thereof are produced by melt extrusion with co- or counter-rotating extruders comprising two screws. Another preferred embodiment is the production by means of extrusion, with extruders comprising one or more screws. These extruders may also comprise kneading elements.
Extrusion is also a well-established production process in pharmaceutical technology and is well known to the person skilled in the art. The person skilled in the art is well aware that during the extrusion process, various parameters, such as the feeding rate, the screw speed, the heating temperature of the different extruder zones (if available), the water content, etc. may be varied in order to produce products of the desired characteristics. The Example section provides for numerous examples of preparations according to the invention that have been produced by extrusion.
The aforementioned parameters will depend on the specific type of extruder used.
During extrusion the temperature of the heating zones, in which the components of the inventive formulation melt, may be between 40 to 120 °C, preferably between 50 to 100 °C, more preferably between 50 to 90 °C, even more preferably between 50 to 70 °C and most preferably between 50 to 65° C, particularly if counter-rotating twin screw extruders (such as a Leistritz Micro 18 GGL) are used. The person skilled in the art is well aware that not every heating zone has to be heated.
Particularly behind the feeder where the components are mixed, cooling at around 25 °C may be necessary. The 'screw speed may vary between 100 to 500 revolutions per minute (rpm), preferably between 100 to 250 rpm, more preferably between 100 to 200 rpm and most preferably around 150 rpm, particularly if counter-rotating twin screw extruders (such as a Leistritz Micro 18 GGL) are used. The geometry and the diameter of the nozzle may be selected as required. The diameter of the nozzle of commonly used extruders typically is between 1 to 10 mm, preferably between 2 to 8 mm and most preferably between 3 to 5 mm. The ratio of length versus diameter of the screw of extruders that may be used for production of inventive preparations is typically around 40:1.
Generally, the temperatures of the heating zones have to be selected such that no temperatures develop that may destroy the pharmaceutically active compounds.
The feeding rate and screw speed will be selected such that the pharmaceutically active compounds are released from the preparations produced by extrusion in a sustained, independent and invariant manner and are storage stable in the matrix . If e.g. the feeding rate is increased, the screw speed may have to be increased correspondingly to ensure the same retardation.
The person skilled in the art knows that all the aforementioned parameters depend on the specific production conditions (extruder type, screw geometry, number of components etc.) and may have to be adapted such that the preparations produced by extrusion provide for a sustained, independent and invariant release as well as for the afore-mentioned storage stability.
The person skilled in the art can infer from the Examples (see below) that by changing the parameters during extrusion and by changing the composition with respect to the compounds that.are substantially responsible for the release behaviour of the preparations, preparations with different release profiles may be obtained.
Thus, the present invention allows to first produce a preparation with a desired release profile for oxycodone and naloxone by e.g. varying the amount of fatty alcohols or the matrix-forming polymer ethylcellulose as well as production parameters such as temperature, screw speed (during extrusion) or pressure power during tablet production.
Once a preparation with the desired release profile has been obtained, the inventive preparations according to the invention allow the person skilled in the art to change the amounts of the preparations with respect to the active compounds as outlined above. Preparations comprising different amounts of the active compounds but of otherwise substantially equal composition, however, will then provide for the features of sustained, invariant and independent release.
The Example section therefore discloses numerous examples showing that preparations with different release profiles may be obtained by changing the amount of e.g. ethylcellulose. Other examples show that once a preparation has been established with desired release profiles, the change in the amount of naloxone will not influence the release behaviour of such preparations if the difference in the amount of the active compound is replaced by pharmaceutically inert excipients such aslactose.
Examples that display highly advantageous embodiments of the invention are set out below. Additionally examples are given that emphasize the advantages of preparations according to the invention compared to common formulations. The examples are not to be interpreted as limiting the possible embodiments of the invention.
_27_ Example I - Production of tablets with different oxycodonelnaloxone amounts in a non-swellable diffusion matrix by spray granulation:
The following amounts of the listed components were used for the production of oxycodonelnaloxone tablets according to the invention.
Preparation Oxy/Nal-0 Oxy/Nal-S Oxy/Nal-10 (designation) oxycodone HCl 20.0 m 20.0 mg 20.0 mg naloxone HCl S.0 mg 10.0 mg Lactose Flow S9.2S m S4.2S m 49.25 mg Lac 100 Povidone 30 S.0 m S.0 mg S.0 mg Surelease~ 10.0 mg solid I0.0 mg solid I0.0 mg solid material material , material Stearyl alcohol 25.0 mg 25.0 mg 25.0 mg Talcum 2.S mg 2.S m 2.S m Mg-Stearate 1.25 mg 1.25 mg 1.25 mg The Surelease~ E-7-7050 polymer mixture used had the following composition.
For the production of tablets oxycodone HCI, naloxone HCl, Povidone 30 and Lactose Flow Lac 100 were mixed in a tumbling mixer (Bohle) and subsequently - 28 _ spray-granulated with Surelease~ E-7-7050 in a fluidized bath granulating device (GPCG3). The material was sieved over a Comill 1.4 mm sieve. An additional granulation step was carried out with melted fatty alcohol in a high-shear mixer (Collette). All tablet cores produced by this approach had a weight of 123 mg, based on dry substance.
Example 2 - Production of tablets with oxycodone and naloxone in a non-swellable diffusion matrix by extrusion:
The following amounts of the listed components were used for the production of the oxycodone/naloxone tablets according to the invention.
Preparation ~ Oxy/Nal-Extr (designation) .
oxycodone HCl 20 mg naloxone HCl 10 mg Kollidon 30 6 mg Lactose Flow Lac 49.25 mg Ethylcellulose 10 m 45 c i Stearyl alcohol 24 mg Talcum 2.5 mg Mg-Stearate 1,25 mg The listed amounts of oxycodone HCI, naloxone HCI, ethylcellulose 45 cpi, Povidone 30, stearyl alcohol and Lactose Flow Lac 100 were mixed in a tumbling mixer (Bohle). This mixture was subsequently extruded with a counter-rotating twin screw extruder of the type Micro 18 GGL (Leistritz AG, Niirnberg, Germany).
The temperature of heating zone 1 was 25°C, of heating zone 2, 50°C, of heating zones 3 to 5, 60°C, of heating zones 6 to 8, 55°C, of heating zone 9, 60°C and of heating zone 10, 65°C. The screw rotating speed was 150 revolutions per minute (rpm), the resulting melt temperature was 87°C, the feed rate was 1.5 kg/h and the diameter of the nozzle opening was 3 mm. The extruded material was sieved with a Frewitt 0.68 x 1.00 mm sieve. The grinded extrudate was then mixed with talcum and magnesium stearate that had been added over a 1 mm hand sieve and was subsequently pressed into tablets. The extruder has a screw geometry, as shown in Fig. 1.
In comparison to the oxycodone/naloxone tablets which also have the Surelease~-based non-swellable diffusion matrix produced by spray granulation (see Example 1), extruded preparations comprise less components.
Example 3 - Release profile of the oxycodone/naloxone tablets from Example 1:
The release of the active compounds was measured over a time period of 12 hours, applying the Basket Method according to USP at pH 1.2 using HPLC. Tablets OxlNal-0, Ox/Nal-5 and Ox/Nal-10 were tested.
One recognizes from Fig. 2 and the values listed in the Table that in the case of a non-swellable diffusion matrix based on Surelease~, the release rates of different oxycodone amounts, independent of the naloxone amount, remain equal (invariant).
Correspondingly, invariant release profiles are observed for naloxone at different oxycodone amounts.
Time Ox/Nal- Ox/Nal-5-Ox/Nal-5-Ox/Nal-10-Ox/Nal-10-(min) 0 O N O N
Oxy Oxy Nal Oxy Nal 15 26.1 24.9 23.5 22.8 24.1 120 62.1 63 61 57.5 60.2 420 91.7 94.5 91.9 89.4 93.5 720 98.1 99.6 96.6 95.7 ~ 100.6 The release values refer to oxycodone or naloxone (line 2) and are given as percentages. The mean value for the release of naloxone at e. g. 420 min is 92,7%.
The maximal deviation at 420 min is 1%. Oxy and Nal stand for oxycodone and naloxone and indicate the active compound which has been measured.
Example 4 - Release profile of oxycodone/naloxone tablets from Example 2 at different pH-values:
The release of active compounds from the tablets was measured over a time period of 12 hours at pH 1.2 or for 1 hour at 1.2 and subsequently for 11 hours at pH
6.5.
Release rates were determined by the basket method according to USP using HPLC.
The following release rates were measured for 12 hours at pH 1.2:
Time Oxy/Nal-Extr-1,2-OOxy/Nal-Extr-1,2-N
(min) Oxy Nal 15 24.1 24.0 120 62.9 63.5 420 92.9 93.9 720 96.9 98.1 The following release rates were measured for 1 hour at pH 1.2 and 11 hours at pH
6.5:
Time Oxy/Nal-Extr-6,5-OOxy/Nal-Extr-6,5-N
(min) Oxy Nal 60 48.1 49.2 120 65.0 64.7 240 83.3 81.8 420 94.1 92.3 The release rates refer to oxycodone and naloxone (line 2) and are given as percentages. Oxy and Nal stand for oxycodone and naloxone and indicate the active compound measured.
The comparison of the values given in the Tables of Example 4 and the Table of Example 3 make clear that independent of the production process, active compounds are released in equal amounts from the preparations. For example, 89.4% of oxycodone is released from spray-granulated tablets (Ox/Nal-10-tablets, see Example 3) at 420 minutes, while 92.9% is released from extruded tablets (Oxy/Nal-Extr-1.2-O, Example 4) at 420 minutes. The release of oxycodone from extruded tablets thus deviates by 1.1% from the mean value of the release of oxycodone from spray-granulated tablets (91.9% at 420 minutes). 93.5% of naloxone is released from spray-granulated tablets (Ox/Nal-10-tablets, see Example 3) at 420 minutes, while 93.9% is released from extruded tablets (Oxy/Nal-Extr.-1.2-O, Example 4) at minutes. The release of naloxone from extruded tablets thus deviates by 1.3%
from the mean value of the release of naloxone from spray-granulated tablets (92.7%
at 420 minutes).
Moreover, one can infer from a comparison of the values of the Tables of Example 4 and from Figures 3a and 3b that independent of the pH value at which the release rates have been measured the release of oxycodone and naloxone remain equal and invariant.
Example 5 - Comparative example: release behaviour of Valoron~ tablets:
The release of the active substances from tablets was monitored over a time period of 7 hours. Valoron~ tablets with 50 mg tilidine and 4 mg naloxone (Ti/Nal-50/4) or 100 mg tilidine and 8 mg naloxone (Ti/Nal-100/8) or 150 mg tilidine and 12 mg naloxone (Ti/Nal-150/12) were tested by the Basket Method according to USP for lh at pH 1.2 and then for additional 6h ~t pH 6.5 using HPLC .
One recognizes from Figures 4A and 4B and the values listed in the Table that in case of a swellable (and possibly erosive) diffusion matrix with relevant amounts of HPMC, the release of different amounts of tilidine varies significantly and is not invariant for different amounts of naloxone. This applies in turn to naloxone.
This means that for this pH the release of the active compounds is not independent of each other.
Time Ti/Nal-Ti/Nal-Ti/Nal-Ti/Nal-Ti/Nal-~Ti/Nal-(min) 50/4-T 50/4-N 100/8-T100/8 150/12-T150/12-N
N
Til Nal Til Nal Til Nal 60 37.2 27.6 33.9 27.3 29.9 23.3 120 47.6 31.7 46.5 33.4 41.5 28.5 180 54.7 37.4 55 41.2 48.2 35 240 59.7 44 68.2 59.5 54.5 40.1 300 65.2 50.6 82.6 72.9 60.5 47.5 360 70.3 58 85.7 82.7 67.2 56.4 420 74.2 60.8 93.1 90.9 84.9 78.9 The release values refer to tilidine or naloxone (line 2) and are given as percentages.
The mean value for the release of naloxone at e. g. 420 min is 78,87%. The maximal deviation at 420 min is 20,4%. Til and Nal stand for tilidine and naloxone and indicate the active compound tested.
Example 6 - Structure comparison of tablets of Examples 1 and 2 with Valoron~
N
tablets by electron microscopy.
For electron microscopy tablets were used that comprised 20 mg oxycodone and mg naloxone and were produced either by spray granulation according to Example (Ox/Nal-10) or by extrusion according to Example 2 (Oxy/Nal-Extr).
Additionally, a Valoron~ N tablet with 100 mg Tilidin and 8 mg Naloxone was used. Figures SA
and SB show different magnifications of scanning electron microscopy pictures of a Ox/Nal-10-tablet with a formulation according to the invention which was produced by spray granulation. Figures 6A and 6B show different magnifications of scanning electron microscopy pictures of a Oxy/Nal-Extr-tablets with a formulation according to the invention, which was produced by extrusion. Figures 7A and 7B show scanning electron microscopy pictures of the Valoron~ N-tablet.
From a comparison of the figures one can clearly see that tablets with a formulation according to the invention have a surface which is substantially finer and more homogeneously structured and which shows fewer cracks than the Valoron~
tablet, regardless of whether the tablets have been produced by spray granulation or extrusion. The structural difference is possibly the reason for the different release behaviours of the different preparations.
Example 7 - Production of tablets with different oxycodone/naloxone amounts in a non-swellable diffusion matrix by extrusion:
The following amounts of the listed components were used for the production of oxycodone/naloxone tablets according to the invention.
Preparation OxN20/1-Extr-AOxN20/1-Extr-BOxN20/1-Extr-COxN20/10-Extr-A
(designation) Oxycodone 20 mg 20 mg 20 mg 20 mg HCl Naloxone HCl 1 mg 1 m 1 mg 10 mg Lactose Flow 58.25 mg 58.25 mg 58.25 mg 49.25 mg Lac 100 I~ollidon~ 6 m 6 mg 6 m 6 mg 30 , Ethylcellulose10 mg 10 mg 10 mg 10 mg Stearly alcohol24 mg " 24 mg 24 m 24 mg ~
Talcum 1.25 m 1.25 mg 1.25 m 1.25 mg M~-Stearate 2.5 mg 2.5 mg ~ 2.5 mg ~ 2.5 mg Extrusion was performed as described above (Example 2) with the following parameters:
OxN20/1-Extr-A: temperature:55-63 C
rpm (screw): 150 rpm feeding rate: 1.5 kg/h OxN20/1-Extr-B: temperature:55-63 C
rpm (screw): 155 rpm feeding rate: 1.5 kg/h OxN20/1-Extr-C: temperature:55-63 C
rpm (screw): 1505rpm feeding rate: 1.5 kg/h OxN20/10-Extr-A: temperature: 55-63 °C
rpm (screw): 160 rpm feeding rate: 1.75 kg/h Tablet production was performed with a common tabletting device with the following parameters:
OxN20/1-Extr-A: rpm: 40 rpm Pressure power: 9 kN
OxN20/1-Extr-B: rpm: 42 rpm Pressure power: 8.9 kN
OxN20/1-Extr-C: rpm: 36 rpm Pressure power: 9 kN
OxN20/10-Extr-A: rpm: 36 rpm Pressure power: 7.5 kN
The release of the active compounds was measured over a time period of 12 hours, applying the Basket Method according to USP at pH 1.3 using HPLC. Tablets OxN20/1-Extr-A, OxN20/1-Extr-B, OxN20/1-Extr-C and OxN20/10-Extr-A were tested.
One recognizes from the values listed in the Table that in the case of a non-swellable diffusion matrix based on ethylcellulose, the release rates of different naloxone amounts, independent of the oxycdone amount, remain substantially equal.
Correspondingly, the preparations provide for an independent and invariant release of the active compounds.
Time OxN20/1- OxN2011- OxN20/1- OxN20/10-(min) Extr-A Extr-B Extr-C Extr-A
Oxy Nal Oxy Nal Oxy Nal Oxy Nal 21.2 25.8 21.7 21.1 19.7 19.3 23.3 24.3 120 56.6 53.8 58.8 57.3 57.7 56.2 64.5 66.9 420 87.2 84.5 94.2 92.6 93.7 91.5 92.7 96.3 720 99.7 96.8 100.1 98 100.6 97.5 93.6 97.4 The release values refer to oxycodone or naloxone (line 2) and are given as .
.
percentages. The mean value for the release of naloxone at e. g. 420 min is 92.3%.
10 The maximal deviation at 420 min is 7.4%. Oxy and Nal stand for oxycodone and naloxone and indicate the active compound which has been measured.
Thus, once a preparation with the desired release profile has been developed, one can change the amount of the active compounds without significantly changing the 15 release profiles of the active compounds. The preparations comprising different amounts of the active compounds still provide for a sustained, independent an invariant release of the active compounds.
Example 8 - Production of tablets with oxycodone/naloxone in a non-swellable diffusion matrix by extrusion:
In the following example it is set out that using formulations according to the present invention, preparations comprising oxycodone and naloxone with particular release behaviours may be obtained.
The following amounts of the listed components were used for the production of oxycodonelnaloxone tablets according to the invention.
Preparation OxN20/1-OxN20/1-OxN20/10-OxN20/10-OxN20/10-OxN20/10-(designation)Extr-D Extr-E Extr-B Extr-C Extr-D Extr-E
oxycodone 20 mg 20 m 20 m 20 mg 20 m~ 20 m HCl naloxone 1 m 1 mg 10 mg 10 m 10 mg 10 mg HCl :,~~', Lactose Flow56.25 56.25 54.25 65.25 60.25 55.25 Lac 100 mg mg mg mg mg I~ollidon~ 7 mg 6 mg 6 mg 7.25 mg 7.25 7.25 mg 30 m Ethylcellulose11 m 12 mg 10 mg 12 mg 12 mg 12 mg Stearyl alcohol24 mg 24 mg 24 mg 28.75 28.75 28.75 mg mg mg Talcum 1.25 1.25 1.25 mg 1.25 mg 1.25 1.25 mg m mg mg Mg-Stearate 2.5 2.5 mg 2.5 mg 2.5 m 2.5 mg 2.5 mg mg Extrusion was performed as described above (Example 2) with the following parameters:
OxN20/1-Extr-D: temperature: 55-63 °C
rpm (screw): 150 rpm feeding rate: 1.5 kg/h OxN20/1-Extr-E: temperature: 55-63 °C
rpm (screw): 150 rpm feeding rate: 1.5 kg/h OxN20/10-Extr-B: temperature: 55-63 °C
rpm (screw): 160 rpm feeding rate: 1.75 kg/h OxN20/10-Extr-C: temperature: 55-63 C
rpm (screw): 160 rpm feeding rate: 1.75 kg/h OxN20/10-Extr-D: temperature: 55-63 C
rpm (screw): 150 rpm feeding rate: 1.5 kg/h OxN20/10-Extr-E: temperature: 55-63 C
rpm (screw): 150 rpm feeding rate: 1.5 kg/h Tablet production was performed with a common tabletting device with the following parameters:
OxN20/1-Extr-D: rpm: 39 rpm Pressure power: 11 kN
OxN20/1-Extr-E: rpm: 39 rpm Pressure power: 10.5 kN
OxN20/10-Extr-B: rpm: 36 rpm Pressure power: 9.5 kN
OxN20/10-Extr-C: rpm: 36 rpm Pressure power: 7.8 kN
OxN20/10-Extr-D: rpm: 39 rpm Pressure power: 9 kN
OxN20/10-Extr-E: rpm: 39 rpm Pressure power: 7.5 kN
The release of the active compounds was measured over a time period of 12 hours, applying the Basket Method according to USP at pH 1.2 using HPLC. Tablets OxN20/1-Extr-D, OxN20/1-Extr-E, OxN20/10-Extr-B, OxN20/10-Extr-C, OxN20/10-Extr-D and OxN20/10-Extr-E were tested.
TimeOxN20/1- OxN20/1- OxN20/10- OxN20/10- OxN20/10- OxN20/10-(min)Extr-D Extr-E Extr-B Extr-C Extr-D Extr-E
Oxy Nal Oxy Nal Ox Nal Oxy Nal Oxy Nal Oxy Nal 15 16.616.2 17.417.226.1 26.821.821.9 18.518.218.4 18.2 120 47.646.9 49.649.771.1 73.061.261.8 52.852.853.3 53.3 420 82.784.5 84.685.794.3 96.693.294.7 86.386.387.2 88.2 720 95 97 95.295.894.9 97.996.497.9 94.894.895.7 96.5 The release values refer to oxycodone or naloxone (line 2) and are given as percentages. Oxy and Nal stand for oxycodone and naloxone and indicate the active compound which has been measured.
The example shows that preparations with particular release profiles may be produced if ethylcellulose and fatty alcohols are used as the matrix-components that essentially influence the release characteristics of the preparations. Once a preparation with desired release characteristics has been obtained the amount of the active compounds may be changed. The preparations will still provide for a sustained, independent and invariant release behaviour (see example 7).
The treatment of severe pain which results from diseases such as cancer, rheumatism and arthritis is central to the treatment of these diseases. The range of pain felt by tumor patients comprises pain of the periosteum and of the bone itself, as well as visceral pain and pain in soft tissues. All such pain forms render the daily life of patients intolerable and often lead to depressive states. Successful pain therapy resulting in a lasting improvement of quality of life for the patients is therefore equally important to the success of a comprehensive therapy, as is the treatment of the actual causes of the disease.
Regarding the importance of a successful pain therapy, the World Health Organization (WHO) has developed a 4-step model for the treatment of patients with tumor pain. This model has proven to be effective in daily routine practice and can be extended to patients suffering from chronic pain or pain forms which result from diseases other than cancer. Depending on the intensity, quality and localization of pain, four steps are distinguished during this therapy, with each next step being indicated if the effect of the pain relief agent used until then is no longer sufficient (Ebell, H. J.; Bayer A. (Ed.): Die Schmerzbehandlung von Tumorpatienten, Thieme 1994 (Supportive Mal3nahmen in der Onkologie, Band 3) and Zech, D.; Grond, S.;
Lynch, J.; Hertel, D.; Lehmann, I~.: Validation of World Health Organisation Guidelines for Cancer Pain Relief: a 10-year prospective study, Pain (1995), 63, 65-76).
According to this 4-step model of the WHO, opioid analgesics take a central role in treating pain. The group of opioid analgesics comprises, besides morphine which represents the prototype of these pharmaceutically active agents, also oxycodone, hydromorphone, nicomorphine, dihydrocodeine, diamorphine, papaveretum, codeine, ethylmorphine, phenylpiperidine and derivatives thereof; methadone, dextropropoxyphene, buprenorphine, pentazocine, tilidine, tramadol and hydrocodone. The ATC-Classification (Anatomical Therapeutic Chemical S Classification) of the WHO indicates whether the pharmaceutically active agent represents an opiod analgesic, or not. The pronounced pain-relieving effect of opioid analgesics is due to the imitation of the effect of endogenous, morphine-like acting substances ("endogenous opioids"), whose physiological function is to control the reception and processing of pain stimuli.
Opioids repress the propagation of pain stimuli. Besides the immediate inhibition of neuronal excitatory signal transduction in the spinal cord caused by opioids, an activation of such nerve tracts is relevant, which project form the brainstem into the spinal cord. This activation results in an inhibition of pain propagation in the spinal cord. Moreover, opioids limit the pain reception of the thalamus and by affecting the limbic system they influence the affective pain evaluation.
Opioid receptors are found at different sites in the body. Receptors of the intestine and brain are of particular importance for pain therapy by opioids, especially as their occupation results in different side effects.
Opioid analgesics are considered to be strong agonists if they bind with high affinity to opioid receptors and induce a strong inhibition of pain reception.
Substances that also bind with high affinity to opioid receptors, but that do not provoke a reduction of pain reception and which thereby counteract the opioid agonists, are designated as antagonists. Depending on the binding behaviour and the induced activity, opioids can be classified as pure agonists, mixed agonists/antagonists and pure antagonists.
Pure antagonists comprise, for example, naltrexone, naloxone, nalmefene, nalorphine, nalbuphine, naloxoneazinen, methylnaltrexone, ketylcyclazocine, norbinaltorphimine, naltrindol, 6-13-naloxol and 6-13-naltrexol (Forth W.;
Henschler, D.; Rummel W.; Starke, K.: Allgemeine and Spezielle Pharmakologie and Toxikologie, 7. Auflage, 1996, Spektrum Akademischer Verlag, Heidelberg Berlin Oxford).
Due to their good analgesic efficiency compounds such as oxycodone, tilidine, buprenorphine and pentazocine, have been used in the form of medicaments for pain therapy. Medicaments such as Oxigesic~ (wherein oxycodone is the analgesic active compound) and Valoron~ (wherein tilidine is the analgesic active compound ) have proven valuable for pain therapy.
However, use of opioid analgesics far pain therapy might go along with undesirable side effects. Thus, long-term use of opioid analgesics can lead to psychological and physical dependence.
Especially the physical dependence of patients suffering from pain to opioid analgesics leads to the development of tolerance, meaning that upon extended intake, increasingly higher doses of the pain relieving agent have to be taken by the patient, in order to experience pain relief. The euphoregenic effect of opioid analgesics often leads to the abuse of pain relievers. Drug abuse and psychological dependence are a common phenomenon, especially among teenagers. These dangerous effects are especially caused by the substances with strong analgesic capacity, and can range from undesired habituation to fully developed addiction. However, these substances are legitimately used for medical purposes and medicine cannot do without them.
Besides the mentioned disadvantages, the use of potent opioid analgesics for pain therapy often also lead to undesirable side effects, such as obstipation, breath depression, sickness and sedation. Less frequently, the urge or the disability to pass water are observed. Different attempts have been made to counteract the habituation processes and the other side effects occurring during pain therapy. This can be done, e.g. by traditional treatment methods. In the case of drug addiction this might be a drug withdrawal treatment, and in the case of obstipation, this might be done by administration of laxatives.
Other attempts aim at minimizing the addictive and habituation forming potential of opioid analgesics, as well as their other side effects by the administration of antagonists which counteract the opioid analgesic. Such antagonists might be naltrexone or naloxone.
There have been numerous proposals and suggestions, how the application of the aforementioned active compounds could be used~to avoid undesired habituation and dependence, or even addiction.
US Patent Nos. 3,773,955 and 3,966,940 suggested to formulate analgesics in combination with naloxone, in order to prevent dependence-promoting effects such as euphoria and the like, upon parenteral application. The avoidance of side effects such as obstipation has not been addressed.
To limit the parenteral abuse of oral application forms, US Patent No.
4,457,933 suggested the combination of morphine with naloxone in defined ranges. The avoidance of side effects such as obstipation has also not been mentioned.
US Patent No. 4,582,835 describes, again in order to avoid abuse, a preparation comprising a combination of buprenorphine and naloxone , that is to be administered either parenterally or sublingually.
European application EP 0 352 361 A1 concerns the treatment of obstipation during pain therapy by the oral application of an opioid analgesic and one antagonist, with the antagonist being a pro-drug form of either naltrexone or naloxone.
Avoidance of abuse of the opioid analgesic is not an issue in this application.
German patent application DE 43 25 465 A1 also concerns the treatment of obstipation during pain therapy using a preparation which comprises an opioid analgesic and an antagonist. The characterizing feature of this disclosure is that the antagonist which can be naloxone, has to be present in higher amounts than the opioid analgesic which is preferably morphine. This is to ensure that the antagonist unfolds its anti-obstipation effect without reducing the analgesic activity of the agonist. The avoidance of abuse.of the opioid analgesic is not an issue in this application.
In order to avoid side effects such as obstipation and breath depression during pain therapy, preparations have been introduced on the market which can be taken orally and comprise an opioid analgesic and the opioid antagonist, naloxone. The medicament Talwin~ of Windrop/Sterling comprises pentazocine and naloxone. The medicament Valoron~ of Godeke comprises a tilidine-naloxone combination.
Besides the potent analgesic effect, the reduction of addictive potential and the avoidance of side effects, medicaments usable for a successful pain therapy should provide for additional characteristics.
Generally, medicaments have to be formulated in a way that the active compounds are stable as long as possible, under standard storage conditions. Medicaments have also to be formulated in a way that the intended release profiles of the active compounds do not change upon long-term storage.
Additionally, (also in the case of agonist/antagonist-combinations) the release profile of each single active compound should be selectable as required. The measures applied in order to achieve this should not hamper or even prevent that the release profiles of additional active compounds (e.g. in the case of combinations of different active compounds) can be chosen as required. Consequently, there should be no mutual dependency of the release profiles.
Medicaments suitable for pain therapy should either contain the active compounds in such amounts or be formulated in such ways hat they have to be taken by the patients only rarely. The easier the' application scheme for a pain reliever is, and the more evident it is for the patient why and how often he should take which tablet, the more exactly he will adhere to the physician's orders. The necessity to take the pain reliever only infrequently, will result in a high willingness of the patient to take the pain reliever (compliance).
Through the use of so called sustained-release formulations, i.e. formulations of medicaments from which the active compounds are released over an extended period of time, it has been tried to lower the frequency by which pain relieving medicaments have to be taken, and thereby to increase the compliance of patients. Such sustained-release formulations also make sense in that the sustained release of an opioid analgesic reduces the addictive potential of this active compound.
This is due to the fact that the addictive potential of an active compound is not defined by the compound itself, but rather by the way it is administered and the pharmaco-dynamics resulting therefrom. Besides the psychotropic effect of an _ 'J _ opioid, the rate by which the brain encounters an opioid, is more decisive criterion for the risk of dependency than the active compound itself (Nolte, T.: STI~-Zeitschrift fiir angewandte Schmerztherapie, 2001, Vol. 2).
The medicament Oxigesic~ of Purdue is a preparation from which the opioid analgesic oxycodone is released in a sustained manner. Due to this formulation, the frequency by which the medicament has to be taken as well as the addictive potential is lowered, however the side effects remain and the danger of developing addiction cannot be excluded, as Oxigesic~ does not contain opioid-antagonists.
According to the already mentioned European patent application EP 0 352 361 A, neither the opioid analgesic nor the antagonist are formulated to be released in a sustained manner. Accordingly, the time period~during which such preparations are effective is limited and preparations have to be taken multiple times per day.
The desired compliance of the patient is not achieved. This application also does not disclose the advantages of formulations of preparations that are characterized by a time-stable and independent release of the active compounds. The storage stability of such preparations is also not addressed by this disclosure.
German patent application DE 43 25 465 A1 discloses formulations according to which obstipation occurring during pain therapy is prevented by the sustained release of the opioid agonist while the antagonist, which is present in excess must not be released in a sustained manner. Due to the high First-Pass-Effect of naloxone, comparably large amounts of this compound have therefore to be used. This application discloses neither the advantages nor the formulations of preparations, which are characterized by time-stable and independent release of the active compounds. The storage stability of such preparations is also not an issue of this _g_ disclosure. A doctor using preparations according to this disclosure has therefore to carry out extensive titration experiments each time he wants to increase the dosage.
The company Godeke offers, under the trademark Valoron~, a pain reliever that comprises a tilidine-naloxone-combination. According to the product literature, a formulation is used from which both active compounds are released in a sustained manner. The matrix used comprises a relevant part of water-swellable material (HPMC) and has therefore to be considered as a swellable (and possibly partially erosive) diffusion matrix. A disadvantage of this known formulation is that tilidine and naloxone, given identical mass ratios but different absolute amounts, show different release profiles. The release rates of the agonist and the antagonist axe not independent from each other, which is probably due to the sustained release formu-lation used. Accordingly, it is necessary for the physician to carry out extensive titration experiments for each individual patient if he wants to increase the dosage even though he does not change the mass ratio of tilidine:naloxone, as he cannot assume that the release profiles of both components will remain constant. The range of therapeutically usable amounts of the analgesic that are available to the doctor is therefore limited.
It is one of the objectives of the present invention to provide a pharmaceutical preparation for pain therapy that, given a high analgesic activity, is characterized by a reduced abuse potential and reduced side effects, said preparation also being characterized by a reduced administration frequency and therefore providing increased compliance, as well as the ability for individual adaptation of the dosage for each patient. A further objective of the present invention is to provide formulations for pharmaceutical preparations usable in pain therapy that make sure that the active compounds of said pharmaceutical preparations are stable over a long storage time, and that the release of the active compounds remain reproducibly invariant and independent from each other even after long-term storage.
The feature combination of the independent claim serves to attain these, and further objectives which can be noted from the ensuing description of the invention.
Preferred embodiments of the invention are defined in the subclaims.
According to the invention, the objectives are attained by providing a storage-stable pharmaceutical preparation comprising oxycodone and naloxone wherein said preparation is formulated such that the active compounds are released in a sustained, invariant and independent manner.
By the combination of oxycodone (in:awanalgesically effective amounts and naloxone it is.ensured that preparations according to the invention show an efficient analgesic activity and that at the same time, common side effects such as obstipation, breath depression and development of addiction are suppressed, or at least significantly reduced. The matrix formulation, which is stable over extended periods of time, ensures permanently that agonist as well as antagonist are always released in predetermined percentages and that their release rates do not influence each other.
Thereby, abuse of the medicament, which requires that the oxycodone can selectively be extracted from the formulation, is prevented. The formulation according to the invention disables selective extraction of the agonist from the preparation without the corresponding amount of the antagonist, independent of the absolute and relative amounts of agonist and antagonist chosen.
Moreover, the formulation of a medicament according to the invention ensures that, given identical relative amounts, the active compounds show equal release profiles, independent of the absolute amount present. Such an independent release behaviour provides a wide range of useable absolute amounts of the analgesic active substance to the physician, given that the optimal agonist/antagonist ratio is known.
Thus, it is possible to comfortably adjust the dosage for each individual patient, either by a step-wise dosage increase or, if necessary, a step-wise dosage reduction. This ability to adjust the dosage for the individual patient is extremely useful from a medical point of view.
The characterizing features of the present invention, which comprise the sustained, invariant and independent release of the active compounds ensure additionally that pharmaceutical preparations produced according to the invention are characterized by a low administration frequency, so that high patient compliance is achieved.
Furthermore, preparations according to the invention allow the doctor to adjust the dosage for individual patients. Preparations according to the invention.
enable use:
over a broad range with respect to the useable absolute amounts of the active .
compounds and ensure that the active compounds, even after long-term storage, become effective with equal release profiles.
According to the present invention, sustained release of active compounds means that pharmaceutically active substances are released from a medicament over a longer period of time than they are from known formulations for immediate release.
Preferably, the release takes place over a time period of two to twenty four hours, of two to twenty hours, especially preferred over a time period of two to sixteen hours or two to twelve hours, with the specifications satisfying the legal and regulating requirements.
According to the invention, formulations of medicaments that ensure such a sustained release of the active compounds from the preparation, are designated as retard formulations, as sustained release formulations or as prolonged release formulations. In the context of the instant invention, "sustained release"
does not mean that the active compounds are released from the formulation or the medicament in a pH-dependent manner. According to the invention, the release of the active compounds rather occurs in a pH-independent manner. According to the invention, the term "sustained release" refers to the release of active compounds from a medicament over an extended period of time. It does not imply the controlled release at a defined place; therefore, it does not mean that the active compounds are either released only in the stomach, or only in the intestine. (Of course, such a release at a defined place could individually be achieved by, e.g., enteric coating of the medicament. However, this presently seems not to be advantageous.) According to the invention, "independent release" means that, given the presence of at least two active compounds, a change of the absolute amount of one compound does not influence the release profiles of the other compounds so that the release profiles of the other compounds are not changed. For formulations according to the invention such an independent release behaviour is independent of the pH
value, for which the release is measured, or of the production process. The pH
independency particularly applies to the acidic range, i.e. for pH values < 7. The release profile (or release behaviour) is defined as the change of the release of the active compound from the formulation with time, with the amount of each active compound released provided in percents of the total amount of the active compound. The release profile is determined by known tests.
Specifically, this means that for example the release profile of oxycodone, as it is observed for an oxycodone/naloxone-combination with 12 milligrams oxycodone and 4 milligrams naloxone, does not change, if a corresponding preparation with the same formulation contains 12 milligrams oxycodone, but 6 milligrams naloxone.
The independent release feature preferably refers to the situation where preparations of substantially equal composition are compared for the release profile.
Preparations of substantially equal composition have different amounts of the active compounds but are otherwise basically the same with respect the components of the composition which essentially influence the release behaviour.
If e.g. the above-mentioned preparations are compared (with the first preparation comprising 12 mg oxycodone and 4 mg naloxone and the second preparation comprising 12 mg oxycodone and 6 mg naloxone) both prepaxations, provided that they have the same total weight, will provide for the same release profile for oxycodone and naloxone if the difference in the naloxone amount is replaced by a component in the formulation that typically does not influence the release behaviour.
As shown in the Example section, the difference in the amount of naloxone~ my be replaced by a typical pharmaceutically inert filler such as lactose without changing the release profiles.
The person skilled in the art is well aware that if the amount of the active compound in which two preparations differ is replaced by a substance that is essential for the release behaviour of the formulation, such as ethylcellulose or a fatty alcohol, differences in the release behaviour may occur. Thus, the independent release feature preferably applies to formulations that have different amounts of the active compounds but are otherwise identical or at least highly similar with respect to the components that essentially influence the release behaviour (given that formulations of the same total weight are compaxed).
According to the invention, "invariant release behaviour" or "invariant release profile" is defined so that the percentage of the absolute amount of each active compound released per time unit does not significantly change and remains sufficiently constant (and thus does not substantially change) if absolute amounts are changed. Sufficiently constant percentages mean that the percentage released per time unit deviates from a mean value by not more than 20%, preferably by not more than 15% and especially preferably by not more than 10%. The mean value is calculated from six measurements of the release profile. Of course, the amount released per time unit has to satisfy the legal and regulatory requirements.
Specifically, this means for example that given an oxycodone/naloxone combination of 12 mg oxycodone and 4 mg naloxone, during the first 4 hours 25% oxycodone and 20% naloxone axe released. If the oxycodone/naloxone combination instead contains 24 mg oxycodone and 8 mg naloxone, during the first 4 hours also 25% oxycodone and 20% naloxone will be released. In both cases the deviation will not be more than.
20% from the mean value (which in this case is 25°f° oxycodone and 20% naloxone).
As outlined for the independent release behaviour, the invariant release feature also preferably refers to a situation where preparations of substantially equal composition are compared. Such preparation differ with respect to the amount of the active compounds, but are of the same or at least highly similar composition with respect to the release-influencing components of the preparation. Typically, the difference in the amount of an active compound will be replaced by the amount of a pharma-ceutical inert excipient which does not substantially influence the release behaviour of the preparation. Such a pharmaceutical excipient may be lactose, which is a typical filler in pharmaceutical preparations. The person skilled in the art is well aware that the invariant release feature may not apply to preparations where the difference in the amount of an active compound is replaced by substances that are known to essentially influence the release behaviour of the preparation, such as ethylcellulose or fatty alcohols.
In the Example section it is set out that if one preparation comprises 20 mg oxycodone and 1 mg naloxone or 20 mg oxycodone and 10 mg naloxone, with the difference in naloxone being replaced by lactose, that the two preparations of identical weight provide for the same release profiles, so that they exhibit a sustained, invariant and independent release behaviour.
According to the invention "storage stable" or "storage stability" means that upon storage under standard conditions (at least two years at room temperature and usual humidity) the amounts of the active compounds of a medicament formulation do not deviate from the initial amounts by more than the values given in the specification or the guidelines of the common Pharmacopoeias. According to the invention, storage stability also means. that a preparation produced according to the invention can be stored under standard conditions (60%~relative humidity, 25°C) as it is required for admission to the market.
According to the invention, "storage stable" or "time stable" also means that after storage under standard conditions the active compounds show release profiles as they would upon immediate use without storage. According to the invention, the admissible fluctuations with respect to the release profile are characterized in that the amount released per time unit fluctuates by no more than 20%, preferably no more than 15% and especially preferably no more than 10 %, with respect to a mean value.
The mean value is calculated from six measurements of the release profile.
Preferably, the release of the active compounds from a sustained release formulation is determined by the Basket Method according to USP at pH 1.2 or pH 6.5 with HPLC.
Storage stability is preferably determined by the Basket Method according to USP at pH 1.2 with HPLC.
According to the invention, a "non-swellable" or "substantially non-swellable"
diffusion matrix is a matrix formulation for which the release of the active compounds is not influenced (or at least not to a relevant degree) by swelling of the matrix (particularly in the physiological fluids of the relevant target sites in the patient's body).
According to the invention, the term "substantially non-swellable" diffusion matrix also refers to a matrix whose volume will increase by approximately 300%, preferably by approximately 200%, more preferably by approximately 100%, by approximately 75% or by approximately 50%, even more preferably by approximately 30% or by approximately 20% and most preferably by approximately 15%, by approximately 10%, by approximately 5% or by approximately 1% in aqueous solutions (and particularly in the physiological fluids of the relevant target sites in the patient's body).
In the context of the present invention, "agonist" or "analgesic" always refers to oxycodone. In the context of the present invention "antagonist" always refers to naloxone.
Preparations produced according to the invention can be applied orally, nasally, rectally and/or by inhalation for use in pain therapy. According to the invention, parenteral application is not envisaged. Especially preferred is a formulation for oral application.
Even though this might not be expressly stated, the term "agonist" or "antagonist"
always comprises pharmaceutical acceptable and equally acting derivatives, salts and the like. If, for example, oxycodone or naloxone is mentioned, this also comprises, besides the free base, their hydrochloride, sulfate, bisulfate, tatrate, nitrate, citrate, bitratrate, phosphate, malate, maleate, hydrobromide, hydrojodide, fumarate, succinate and the like.
According to the invention, agonists and antagonists are formulated in a way that they are released from the resulting pharmaceutical preparation in a sustained, independent and invariant manner. This does not mean that the antagonist is in excess compared to the agonist. On the contrary, it is preferred that in formulations comprising an agonist/antagonist combination, that show a release profile in accordance with the invention, the agonist is in excess compared to the antagonist.
The excess of the agonist is defined based on the amount of the unit dosage of the antagonist present in the combination preparation. The extent of the excess of the opioid agonist is usually given in terms of the weight ratio of agonist to antagonist.
In the case of oxycodone and naloxone, preferred weight ratios of agonist to antagonist lie within a weight ratio range of 25:1 at maximum, especially preferred are the weight ratio ranges 15:1, 10:1, 5:1, 4:1, 3:1, 2:1 and 1:1.
The absolute amounts of agonist and antagonist to be used depend on the choice of the active compounds. According to the invention, care has to be taken that agonist and antagonist are released from the pharmaceutical preparation that has been formulated for sustained release, only in an independent and invariant manner.
If oxycodone and naloxone are used for a combination preparation, preferably between 10 and 150 mg, especially preferably between 10 and 80 mg of oxycodone (typical amounts for use) and preferably between 1 and 50 mg naloxone per unit dosage are used.
In other preferred embodiments of the invention, the preparations may comprise between 5 and 50 mg of oxycodone, between 10 and 40 mg of oxycodone, between and 30 mg of oxycodone or approximately 20 mg of oxycodone. Preferred embodiments of the invention may also comprise preparations with between 1 and 10 mg naloxone, 1 and 30 mg naloxone, 1 and 20 mg naloxone or between 1 and 10 mg naloxone per unit dosage.
According to the invention, the ratio between oxycodone and naloxone has to be chosen in such a way that release profiles for both active substances in accordance with the invention are guaranteed and that the agonist can display its analgesic effect while the amount of the antagonist is chosen in such a way that habituation-or addiction-promoting effects and side effects of the agonist are reduced or abolished, without (substantially) affecting the analgesic effect of the agonist.
According to the invention, development of habituation and addiction as well as obstipation and breath depression are to be considered as side effects of analgesically effective opioid agonists.
According to the invention, generally common formulations can be used, given that these formulations ensure that the active compounds are released from the preparation in a sustained, independent and invariant manner. According to the invention, those formulations have to be chosen such that the active compounds are storage stable.
Matrix-based retardation formulations may preferably be used as formulations that provide a release of agonist and antagonist in accordance with the invention.
According to the invention, especially preferred are formulations based on a substantially non-swellable diffusion matrix. At the moment, formulations with an erosive matrix or a swellable diffusion matrix are not preferred.
According to the invention, the matrix that provides the sustained release of the active compounds, has to be chosen in such a way that the release of the active compounds occurs in a sustained, independent and invariant manner. Preferably such matrices comprise polymers based on ethylcellulose, with ethylcellulose being an especially preferred polymer. Specifically preferred are matrices comprising polymers as they are available on the market under the trademark Surelease~.
Particularly preferred is 'the use of Surelease~E-7-7050 Formulations with a release behaviour according to the invention comprise particularly matrices that comprise ethylcellulose and at least one fatty alcohol as the components that essentially influence the release characteristics of the matrix. The amounts of ethylcellulose and the at least one fatty alcohol may significantly vary so that preparations with different release profiles may be achieved. Even though the inventive preparations usually will comprise both of the afore-mentioned components, in some cases it may be preferred that the preparations comprise only ethylcellulose or the fatty alcohol(s) as the release determining components.
Matrices based on polymethacrylate (as, e.g. Eudragit~RS30D and Eudragit~RL30D) or matrices which comprise relevant amounts of water-swellable material, especially of hydroxyalkyl cellulose derivates such as HPMC, are presently preferably avoided according to the invention.
Matrices that are in accordance with the invention can be used to produce preparations that release active compounds in a sustained, independent and invariant manner and that release equal amounts of the active compounds per time unit.
Specifically, this means that in the case of a oxycodone/naloxone combination containing 12 mg oxycodone and 4 mg naloxone, 25% oxycodone and 25% naloxone are released within the first 4 hours. Correspondingly, in the case of a oxycodone/naloxone combination containing 24 mg oxycodone and 8 mg naloxone, 25% oxycodone and 25% naloxone are released during the first 4 hours, with the deviation in both cases being no more than 20% of the mean value (which in this case is 25% oxycodone or naloxone).
Such an equal release behaviour for both active compounds may be desirable for medical aspects.
A preferred embodiment of the invention relates to preparations that release 1 % to 40%, preferably 5% to 35%, more preferably between 10% and 30% and even more preferably between 15% and 25% of oxycodone and/or naloxone after 15 minutes.
In other preferred embodiments of the invention, 15% to 20%, 20% to 25%, approximately 15%, approximately 20% or approximately 25% of oxycodone and/or naloxone are released after 15 minutes.
Another preferred embodiment of the invention relates to preparations that release between 25% to 65%, preferably between 30% to 60%, more preferably between 35% to 55% and even more preferably between 40% to 50% of oxycodone and/or naloxone after one hour. Preferred embodiments of the invention also relate to preparations that release between 40% to 45%, 45% to 50%, approximately 40%, approximately 45% or approximately 50% of oxycodone and/or naloxone after one hour.
Yet another preferred embodiment of the invention relates to preparations that release between 40% to 80%, preferably between 45% to 75%, more preferably between 45% to 70% and even more preferably between 45% to 50%, 50% to 55%, 55% to 60%, 60% to 65% or 65% to 70% of oxycodone and/or naloxone after 2 hours. Preferred embodiments also comprise preparations that release approximately 45%, approximately 50%, approximately 55%, approximately 60%, approximately65% or approximately 70% of oxycodone and/or naloxone after 2 hours.
One preferred embodiment of the invention relates to preparations that release 70%
to 100%, preferably between 75% to 95%, more preferably between 80% to 95%, and even more preferably between 80% and 90% of oxycodone and/or naloxone after 4 hours. Preferred embodiments of the invention also relate to preparations that release between 80% to 85%, 85% to 90%, approximately 80%, approximately 85%
or approximately 90% of oxcodone and/or naloxone after 4 hours.
One preferred embodiment of the invention also relates to preparations that release between 70% to 100%, preferably between 75% to 100%, more preferably between 80% to 95% and even more preferably between 80% to 85%, between 85% to 90%
or between 90% to 95% of oxycodone and/or naloxone after 7 hours. Preferred embodiments of the invention also relate to preparations that release approximately 80%, approximately 85%, approximately 90% or approximately 95% of oxycodone and/or naloxone after 7 hours.
Yet another preferred embodiment of the invention relates to preparations that release between 85% to 100%, preferably between 90% to 100%, more preferably between 95% to 100% and even more preferably approximately 95% or 100% of oxycodone and/or naloxone after 12 hours.
According to the invention, formulations that provide a release of the active compounds in accordance with the invention may comprise, besides the matrix forming polymers, fillers and additional substances, such as granulating aids, lubricants, dyes, flowing agents and plasticizers.
Lactose, glucose or saccharose, starches and their hydrolysates, microcrystalline cellulose, cellatose, sugar alcohols such as sorbitol or mannitol, polysoluble calcium salts like calciumhydrogenphosphate, dicalcium- or tricalciumphosphat may be used as fillers.
Povidone may be used as granulating aid.
Highly-disperse silica (Aerosil~), talcum, corn starch, magnesium oxide and magnesium- or calcium stearate may preferably be used as flowing agents or lubricants.
Magnesium stearate and/or calcium stearate can preferably be used as lubricants.
Fatty acids like stearic acid, or fats like hydrated castor oil can also preferably be used.
Polyethylene glycols and fatty alcohols like cetyl and/or stearyl alcohol and/
or cetostearyl alcohol can also be used as additional substances that influence retardation.
_ 22 _ If fillers and additional substances such as dyes and the mentioned lubricants, flowing agents and plasticizers are used, care has to be taken that according to the invention only such combinations together with the matrix forming substance and/or the matrix forming substances are used, which ensure release profiles of the active compounds in accordance with the invention.
All these additional components of the formulations will be chosen in such a way that the release matrix receives the character of a substantially non-water-or non-buffer-swellable and non-erosive diffusion matrix.
According to the invention, a formulation is especially preferred that comprises ethylcellulose or Surelease~ E-7-7050 as a matrix-building substance, stearyl alcohol as fatty alcohol, magnesium stearate as lubricant, lactose as filler and povidone as a granulating aid.
Preparations in accordance with the invention can be produced as all common application forms which, on principle, are suitable for retardation formulations and which ensure that the active compounds are released in a manner in accordance with the invention. Especially suitable are tablets, mufti-layer tablets and capsules.
Additional application forms like granules or powders can be used, with only those applications forms being admissible that provide a sufficient retardation and a release behaviour in accordance with the invention.
Pharmaceutical preparations may also comprise film coatings. However, it has to be ensured that the film coatings do not negatively influence the release properties of the active compounds from the matrix and the storage stability of the active compounds within the matrix. Such film coatings may be colored or may comprise a initial dosage of the active compounds if required. The active compounds of this initial dosage will be immediately released so that the therapeutically effective blood plasma level is reached very quickly.
Pharmaceutical preparations or preliminary stages thereof which are in accordance with the invention can be produced by build-up or break-down granulation. A
preferred embodiment is the production by spray granulation with subsequent drying of the granules. Another preferred embodiment is the production of granules by build-up granulation in a drum or on a granulating disk. The granules may then be pressed into e.g. tablets using appropriate additional substances and procedures.
The person skilled in the art is familiar with granulating technology as applied to pharmaceutical technology. The embodiment examples (see below) disclose specific embodiments of the invention. ~ I-Iowever, it is well within the scope of the person skilled in the art to adapt the parameters of the process in order to achieve specific purposes.
Production of pharmaceutical preparations or preliminary stages thereof, which are in accordance with the invention, by extrusion technology is especially advantageous.
In one preferred embodiment, pharmaceutical preparations or preliminary stages thereof are produced by melt extrusion with co- or counter-rotating extruders comprising two screws. Another preferred embodiment is the production by means of extrusion, with extruders comprising one or more screws. These extruders may also comprise kneading elements.
Extrusion is also a well-established production process in pharmaceutical technology and is well known to the person skilled in the art. The person skilled in the art is well aware that during the extrusion process, various parameters, such as the feeding rate, the screw speed, the heating temperature of the different extruder zones (if available), the water content, etc. may be varied in order to produce products of the desired characteristics. The Example section provides for numerous examples of preparations according to the invention that have been produced by extrusion.
The aforementioned parameters will depend on the specific type of extruder used.
During extrusion the temperature of the heating zones, in which the components of the inventive formulation melt, may be between 40 to 120 °C, preferably between 50 to 100 °C, more preferably between 50 to 90 °C, even more preferably between 50 to 70 °C and most preferably between 50 to 65° C, particularly if counter-rotating twin screw extruders (such as a Leistritz Micro 18 GGL) are used. The person skilled in the art is well aware that not every heating zone has to be heated.
Particularly behind the feeder where the components are mixed, cooling at around 25 °C may be necessary. The 'screw speed may vary between 100 to 500 revolutions per minute (rpm), preferably between 100 to 250 rpm, more preferably between 100 to 200 rpm and most preferably around 150 rpm, particularly if counter-rotating twin screw extruders (such as a Leistritz Micro 18 GGL) are used. The geometry and the diameter of the nozzle may be selected as required. The diameter of the nozzle of commonly used extruders typically is between 1 to 10 mm, preferably between 2 to 8 mm and most preferably between 3 to 5 mm. The ratio of length versus diameter of the screw of extruders that may be used for production of inventive preparations is typically around 40:1.
Generally, the temperatures of the heating zones have to be selected such that no temperatures develop that may destroy the pharmaceutically active compounds.
The feeding rate and screw speed will be selected such that the pharmaceutically active compounds are released from the preparations produced by extrusion in a sustained, independent and invariant manner and are storage stable in the matrix . If e.g. the feeding rate is increased, the screw speed may have to be increased correspondingly to ensure the same retardation.
The person skilled in the art knows that all the aforementioned parameters depend on the specific production conditions (extruder type, screw geometry, number of components etc.) and may have to be adapted such that the preparations produced by extrusion provide for a sustained, independent and invariant release as well as for the afore-mentioned storage stability.
The person skilled in the art can infer from the Examples (see below) that by changing the parameters during extrusion and by changing the composition with respect to the compounds that.are substantially responsible for the release behaviour of the preparations, preparations with different release profiles may be obtained.
Thus, the present invention allows to first produce a preparation with a desired release profile for oxycodone and naloxone by e.g. varying the amount of fatty alcohols or the matrix-forming polymer ethylcellulose as well as production parameters such as temperature, screw speed (during extrusion) or pressure power during tablet production.
Once a preparation with the desired release profile has been obtained, the inventive preparations according to the invention allow the person skilled in the art to change the amounts of the preparations with respect to the active compounds as outlined above. Preparations comprising different amounts of the active compounds but of otherwise substantially equal composition, however, will then provide for the features of sustained, invariant and independent release.
The Example section therefore discloses numerous examples showing that preparations with different release profiles may be obtained by changing the amount of e.g. ethylcellulose. Other examples show that once a preparation has been established with desired release profiles, the change in the amount of naloxone will not influence the release behaviour of such preparations if the difference in the amount of the active compound is replaced by pharmaceutically inert excipients such aslactose.
Examples that display highly advantageous embodiments of the invention are set out below. Additionally examples are given that emphasize the advantages of preparations according to the invention compared to common formulations. The examples are not to be interpreted as limiting the possible embodiments of the invention.
_27_ Example I - Production of tablets with different oxycodonelnaloxone amounts in a non-swellable diffusion matrix by spray granulation:
The following amounts of the listed components were used for the production of oxycodonelnaloxone tablets according to the invention.
Preparation Oxy/Nal-0 Oxy/Nal-S Oxy/Nal-10 (designation) oxycodone HCl 20.0 m 20.0 mg 20.0 mg naloxone HCl S.0 mg 10.0 mg Lactose Flow S9.2S m S4.2S m 49.25 mg Lac 100 Povidone 30 S.0 m S.0 mg S.0 mg Surelease~ 10.0 mg solid I0.0 mg solid I0.0 mg solid material material , material Stearyl alcohol 25.0 mg 25.0 mg 25.0 mg Talcum 2.S mg 2.S m 2.S m Mg-Stearate 1.25 mg 1.25 mg 1.25 mg The Surelease~ E-7-7050 polymer mixture used had the following composition.
For the production of tablets oxycodone HCI, naloxone HCl, Povidone 30 and Lactose Flow Lac 100 were mixed in a tumbling mixer (Bohle) and subsequently - 28 _ spray-granulated with Surelease~ E-7-7050 in a fluidized bath granulating device (GPCG3). The material was sieved over a Comill 1.4 mm sieve. An additional granulation step was carried out with melted fatty alcohol in a high-shear mixer (Collette). All tablet cores produced by this approach had a weight of 123 mg, based on dry substance.
Example 2 - Production of tablets with oxycodone and naloxone in a non-swellable diffusion matrix by extrusion:
The following amounts of the listed components were used for the production of the oxycodone/naloxone tablets according to the invention.
Preparation ~ Oxy/Nal-Extr (designation) .
oxycodone HCl 20 mg naloxone HCl 10 mg Kollidon 30 6 mg Lactose Flow Lac 49.25 mg Ethylcellulose 10 m 45 c i Stearyl alcohol 24 mg Talcum 2.5 mg Mg-Stearate 1,25 mg The listed amounts of oxycodone HCI, naloxone HCI, ethylcellulose 45 cpi, Povidone 30, stearyl alcohol and Lactose Flow Lac 100 were mixed in a tumbling mixer (Bohle). This mixture was subsequently extruded with a counter-rotating twin screw extruder of the type Micro 18 GGL (Leistritz AG, Niirnberg, Germany).
The temperature of heating zone 1 was 25°C, of heating zone 2, 50°C, of heating zones 3 to 5, 60°C, of heating zones 6 to 8, 55°C, of heating zone 9, 60°C and of heating zone 10, 65°C. The screw rotating speed was 150 revolutions per minute (rpm), the resulting melt temperature was 87°C, the feed rate was 1.5 kg/h and the diameter of the nozzle opening was 3 mm. The extruded material was sieved with a Frewitt 0.68 x 1.00 mm sieve. The grinded extrudate was then mixed with talcum and magnesium stearate that had been added over a 1 mm hand sieve and was subsequently pressed into tablets. The extruder has a screw geometry, as shown in Fig. 1.
In comparison to the oxycodone/naloxone tablets which also have the Surelease~-based non-swellable diffusion matrix produced by spray granulation (see Example 1), extruded preparations comprise less components.
Example 3 - Release profile of the oxycodone/naloxone tablets from Example 1:
The release of the active compounds was measured over a time period of 12 hours, applying the Basket Method according to USP at pH 1.2 using HPLC. Tablets OxlNal-0, Ox/Nal-5 and Ox/Nal-10 were tested.
One recognizes from Fig. 2 and the values listed in the Table that in the case of a non-swellable diffusion matrix based on Surelease~, the release rates of different oxycodone amounts, independent of the naloxone amount, remain equal (invariant).
Correspondingly, invariant release profiles are observed for naloxone at different oxycodone amounts.
Time Ox/Nal- Ox/Nal-5-Ox/Nal-5-Ox/Nal-10-Ox/Nal-10-(min) 0 O N O N
Oxy Oxy Nal Oxy Nal 15 26.1 24.9 23.5 22.8 24.1 120 62.1 63 61 57.5 60.2 420 91.7 94.5 91.9 89.4 93.5 720 98.1 99.6 96.6 95.7 ~ 100.6 The release values refer to oxycodone or naloxone (line 2) and are given as percentages. The mean value for the release of naloxone at e. g. 420 min is 92,7%.
The maximal deviation at 420 min is 1%. Oxy and Nal stand for oxycodone and naloxone and indicate the active compound which has been measured.
Example 4 - Release profile of oxycodone/naloxone tablets from Example 2 at different pH-values:
The release of active compounds from the tablets was measured over a time period of 12 hours at pH 1.2 or for 1 hour at 1.2 and subsequently for 11 hours at pH
6.5.
Release rates were determined by the basket method according to USP using HPLC.
The following release rates were measured for 12 hours at pH 1.2:
Time Oxy/Nal-Extr-1,2-OOxy/Nal-Extr-1,2-N
(min) Oxy Nal 15 24.1 24.0 120 62.9 63.5 420 92.9 93.9 720 96.9 98.1 The following release rates were measured for 1 hour at pH 1.2 and 11 hours at pH
6.5:
Time Oxy/Nal-Extr-6,5-OOxy/Nal-Extr-6,5-N
(min) Oxy Nal 60 48.1 49.2 120 65.0 64.7 240 83.3 81.8 420 94.1 92.3 The release rates refer to oxycodone and naloxone (line 2) and are given as percentages. Oxy and Nal stand for oxycodone and naloxone and indicate the active compound measured.
The comparison of the values given in the Tables of Example 4 and the Table of Example 3 make clear that independent of the production process, active compounds are released in equal amounts from the preparations. For example, 89.4% of oxycodone is released from spray-granulated tablets (Ox/Nal-10-tablets, see Example 3) at 420 minutes, while 92.9% is released from extruded tablets (Oxy/Nal-Extr-1.2-O, Example 4) at 420 minutes. The release of oxycodone from extruded tablets thus deviates by 1.1% from the mean value of the release of oxycodone from spray-granulated tablets (91.9% at 420 minutes). 93.5% of naloxone is released from spray-granulated tablets (Ox/Nal-10-tablets, see Example 3) at 420 minutes, while 93.9% is released from extruded tablets (Oxy/Nal-Extr.-1.2-O, Example 4) at minutes. The release of naloxone from extruded tablets thus deviates by 1.3%
from the mean value of the release of naloxone from spray-granulated tablets (92.7%
at 420 minutes).
Moreover, one can infer from a comparison of the values of the Tables of Example 4 and from Figures 3a and 3b that independent of the pH value at which the release rates have been measured the release of oxycodone and naloxone remain equal and invariant.
Example 5 - Comparative example: release behaviour of Valoron~ tablets:
The release of the active substances from tablets was monitored over a time period of 7 hours. Valoron~ tablets with 50 mg tilidine and 4 mg naloxone (Ti/Nal-50/4) or 100 mg tilidine and 8 mg naloxone (Ti/Nal-100/8) or 150 mg tilidine and 12 mg naloxone (Ti/Nal-150/12) were tested by the Basket Method according to USP for lh at pH 1.2 and then for additional 6h ~t pH 6.5 using HPLC .
One recognizes from Figures 4A and 4B and the values listed in the Table that in case of a swellable (and possibly erosive) diffusion matrix with relevant amounts of HPMC, the release of different amounts of tilidine varies significantly and is not invariant for different amounts of naloxone. This applies in turn to naloxone.
This means that for this pH the release of the active compounds is not independent of each other.
Time Ti/Nal-Ti/Nal-Ti/Nal-Ti/Nal-Ti/Nal-~Ti/Nal-(min) 50/4-T 50/4-N 100/8-T100/8 150/12-T150/12-N
N
Til Nal Til Nal Til Nal 60 37.2 27.6 33.9 27.3 29.9 23.3 120 47.6 31.7 46.5 33.4 41.5 28.5 180 54.7 37.4 55 41.2 48.2 35 240 59.7 44 68.2 59.5 54.5 40.1 300 65.2 50.6 82.6 72.9 60.5 47.5 360 70.3 58 85.7 82.7 67.2 56.4 420 74.2 60.8 93.1 90.9 84.9 78.9 The release values refer to tilidine or naloxone (line 2) and are given as percentages.
The mean value for the release of naloxone at e. g. 420 min is 78,87%. The maximal deviation at 420 min is 20,4%. Til and Nal stand for tilidine and naloxone and indicate the active compound tested.
Example 6 - Structure comparison of tablets of Examples 1 and 2 with Valoron~
N
tablets by electron microscopy.
For electron microscopy tablets were used that comprised 20 mg oxycodone and mg naloxone and were produced either by spray granulation according to Example (Ox/Nal-10) or by extrusion according to Example 2 (Oxy/Nal-Extr).
Additionally, a Valoron~ N tablet with 100 mg Tilidin and 8 mg Naloxone was used. Figures SA
and SB show different magnifications of scanning electron microscopy pictures of a Ox/Nal-10-tablet with a formulation according to the invention which was produced by spray granulation. Figures 6A and 6B show different magnifications of scanning electron microscopy pictures of a Oxy/Nal-Extr-tablets with a formulation according to the invention, which was produced by extrusion. Figures 7A and 7B show scanning electron microscopy pictures of the Valoron~ N-tablet.
From a comparison of the figures one can clearly see that tablets with a formulation according to the invention have a surface which is substantially finer and more homogeneously structured and which shows fewer cracks than the Valoron~
tablet, regardless of whether the tablets have been produced by spray granulation or extrusion. The structural difference is possibly the reason for the different release behaviours of the different preparations.
Example 7 - Production of tablets with different oxycodone/naloxone amounts in a non-swellable diffusion matrix by extrusion:
The following amounts of the listed components were used for the production of oxycodone/naloxone tablets according to the invention.
Preparation OxN20/1-Extr-AOxN20/1-Extr-BOxN20/1-Extr-COxN20/10-Extr-A
(designation) Oxycodone 20 mg 20 mg 20 mg 20 mg HCl Naloxone HCl 1 mg 1 m 1 mg 10 mg Lactose Flow 58.25 mg 58.25 mg 58.25 mg 49.25 mg Lac 100 I~ollidon~ 6 m 6 mg 6 m 6 mg 30 , Ethylcellulose10 mg 10 mg 10 mg 10 mg Stearly alcohol24 mg " 24 mg 24 m 24 mg ~
Talcum 1.25 m 1.25 mg 1.25 m 1.25 mg M~-Stearate 2.5 mg 2.5 mg ~ 2.5 mg ~ 2.5 mg Extrusion was performed as described above (Example 2) with the following parameters:
OxN20/1-Extr-A: temperature:55-63 C
rpm (screw): 150 rpm feeding rate: 1.5 kg/h OxN20/1-Extr-B: temperature:55-63 C
rpm (screw): 155 rpm feeding rate: 1.5 kg/h OxN20/1-Extr-C: temperature:55-63 C
rpm (screw): 1505rpm feeding rate: 1.5 kg/h OxN20/10-Extr-A: temperature: 55-63 °C
rpm (screw): 160 rpm feeding rate: 1.75 kg/h Tablet production was performed with a common tabletting device with the following parameters:
OxN20/1-Extr-A: rpm: 40 rpm Pressure power: 9 kN
OxN20/1-Extr-B: rpm: 42 rpm Pressure power: 8.9 kN
OxN20/1-Extr-C: rpm: 36 rpm Pressure power: 9 kN
OxN20/10-Extr-A: rpm: 36 rpm Pressure power: 7.5 kN
The release of the active compounds was measured over a time period of 12 hours, applying the Basket Method according to USP at pH 1.3 using HPLC. Tablets OxN20/1-Extr-A, OxN20/1-Extr-B, OxN20/1-Extr-C and OxN20/10-Extr-A were tested.
One recognizes from the values listed in the Table that in the case of a non-swellable diffusion matrix based on ethylcellulose, the release rates of different naloxone amounts, independent of the oxycdone amount, remain substantially equal.
Correspondingly, the preparations provide for an independent and invariant release of the active compounds.
Time OxN20/1- OxN2011- OxN20/1- OxN20/10-(min) Extr-A Extr-B Extr-C Extr-A
Oxy Nal Oxy Nal Oxy Nal Oxy Nal 21.2 25.8 21.7 21.1 19.7 19.3 23.3 24.3 120 56.6 53.8 58.8 57.3 57.7 56.2 64.5 66.9 420 87.2 84.5 94.2 92.6 93.7 91.5 92.7 96.3 720 99.7 96.8 100.1 98 100.6 97.5 93.6 97.4 The release values refer to oxycodone or naloxone (line 2) and are given as .
.
percentages. The mean value for the release of naloxone at e. g. 420 min is 92.3%.
10 The maximal deviation at 420 min is 7.4%. Oxy and Nal stand for oxycodone and naloxone and indicate the active compound which has been measured.
Thus, once a preparation with the desired release profile has been developed, one can change the amount of the active compounds without significantly changing the 15 release profiles of the active compounds. The preparations comprising different amounts of the active compounds still provide for a sustained, independent an invariant release of the active compounds.
Example 8 - Production of tablets with oxycodone/naloxone in a non-swellable diffusion matrix by extrusion:
In the following example it is set out that using formulations according to the present invention, preparations comprising oxycodone and naloxone with particular release behaviours may be obtained.
The following amounts of the listed components were used for the production of oxycodonelnaloxone tablets according to the invention.
Preparation OxN20/1-OxN20/1-OxN20/10-OxN20/10-OxN20/10-OxN20/10-(designation)Extr-D Extr-E Extr-B Extr-C Extr-D Extr-E
oxycodone 20 mg 20 m 20 m 20 mg 20 m~ 20 m HCl naloxone 1 m 1 mg 10 mg 10 m 10 mg 10 mg HCl :,~~', Lactose Flow56.25 56.25 54.25 65.25 60.25 55.25 Lac 100 mg mg mg mg mg I~ollidon~ 7 mg 6 mg 6 mg 7.25 mg 7.25 7.25 mg 30 m Ethylcellulose11 m 12 mg 10 mg 12 mg 12 mg 12 mg Stearyl alcohol24 mg 24 mg 24 mg 28.75 28.75 28.75 mg mg mg Talcum 1.25 1.25 1.25 mg 1.25 mg 1.25 1.25 mg m mg mg Mg-Stearate 2.5 2.5 mg 2.5 mg 2.5 m 2.5 mg 2.5 mg mg Extrusion was performed as described above (Example 2) with the following parameters:
OxN20/1-Extr-D: temperature: 55-63 °C
rpm (screw): 150 rpm feeding rate: 1.5 kg/h OxN20/1-Extr-E: temperature: 55-63 °C
rpm (screw): 150 rpm feeding rate: 1.5 kg/h OxN20/10-Extr-B: temperature: 55-63 °C
rpm (screw): 160 rpm feeding rate: 1.75 kg/h OxN20/10-Extr-C: temperature: 55-63 C
rpm (screw): 160 rpm feeding rate: 1.75 kg/h OxN20/10-Extr-D: temperature: 55-63 C
rpm (screw): 150 rpm feeding rate: 1.5 kg/h OxN20/10-Extr-E: temperature: 55-63 C
rpm (screw): 150 rpm feeding rate: 1.5 kg/h Tablet production was performed with a common tabletting device with the following parameters:
OxN20/1-Extr-D: rpm: 39 rpm Pressure power: 11 kN
OxN20/1-Extr-E: rpm: 39 rpm Pressure power: 10.5 kN
OxN20/10-Extr-B: rpm: 36 rpm Pressure power: 9.5 kN
OxN20/10-Extr-C: rpm: 36 rpm Pressure power: 7.8 kN
OxN20/10-Extr-D: rpm: 39 rpm Pressure power: 9 kN
OxN20/10-Extr-E: rpm: 39 rpm Pressure power: 7.5 kN
The release of the active compounds was measured over a time period of 12 hours, applying the Basket Method according to USP at pH 1.2 using HPLC. Tablets OxN20/1-Extr-D, OxN20/1-Extr-E, OxN20/10-Extr-B, OxN20/10-Extr-C, OxN20/10-Extr-D and OxN20/10-Extr-E were tested.
TimeOxN20/1- OxN20/1- OxN20/10- OxN20/10- OxN20/10- OxN20/10-(min)Extr-D Extr-E Extr-B Extr-C Extr-D Extr-E
Oxy Nal Oxy Nal Ox Nal Oxy Nal Oxy Nal Oxy Nal 15 16.616.2 17.417.226.1 26.821.821.9 18.518.218.4 18.2 120 47.646.9 49.649.771.1 73.061.261.8 52.852.853.3 53.3 420 82.784.5 84.685.794.3 96.693.294.7 86.386.387.2 88.2 720 95 97 95.295.894.9 97.996.497.9 94.894.895.7 96.5 The release values refer to oxycodone or naloxone (line 2) and are given as percentages. Oxy and Nal stand for oxycodone and naloxone and indicate the active compound which has been measured.
The example shows that preparations with particular release profiles may be produced if ethylcellulose and fatty alcohols are used as the matrix-components that essentially influence the release characteristics of the preparations. Once a preparation with desired release characteristics has been obtained the amount of the active compounds may be changed. The preparations will still provide for a sustained, independent and invariant release behaviour (see example 7).
Claims (83)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. An oral pharmaceutical preparation comprising a combination of: (i) oxycodone or its pharmaceutically acceptable salts, and (ii) naloxone or its pharmaceutically acceptable salts, the combination comprised in a controlled release formulation that provides a sustained and invariant release of both of (i) and (ii), wherein: (i) is present in an amount range of about 5 to about 80 mg, and (i) and (ii) are present in a weight ratio of 2:1.
2. The oral pharmaceutical preparation defined in claim 1, wherein oxycodone or its pharmaceutically acceptable salts is present in an amount in the range of from 5 to 50 mg.
3. The oral pharmaceutical preparation defined in claim 1, wherein oxycodone or its pharmaceutically acceptable salts is present in an amount in the range of from to 40 mg.
4. The oral pharmaceutical preparation defined in claim 1, wherein oxycodone or its pharmaceutically acceptable salts is present in an amount in the range of from to 30 mg.
5. The oral pharmaceutical preparation defined in claim 1, wherein oxycodone or its pharmaceutically acceptable salts is present in an amount of 20 mg.
6. The oral pharmaceutical preparation defined in any one of claims 1-5, wherein oxycodone is present in the form of a pharmaceutically acceptable salt thereof.
7. The oral pharmaceutical preparation defined in Claim 6, wherein oxycodone is present as a pharmaceutically acceptable salt selected from the group consisting of hydrochloride, sulfate, bisulfate, tartrate, nitrate, citrate, bitatrate, phosphate, malate, maleate, hydrobromide, hydroiodide, fumarate and succinate.
8. The oral pharmaceutical preparation defined in any one of claims 1-5, wherein oxycodone is present in the form of oxycodone hydrochloride.
9. The oral pharmaceutical preparation defined in any one of claims 1-8, wherein naloxone is present in the form of a pharmaceutically acceptable salt thereof.
10. The oral pharmaceutical preparation defined in Claim 9, wherein naloxone is present as a pharmaceutically acceptable salt selected from the group consisting of hydrochloride, sulfate, bisulfate, tartrate, nitrate, citrate, bitatrate, phosphate, malate, maleate, hydrobromide, hydroiodide, fumarate and succinate.
11. The oral pharmaceutical preparation defined in any one of claims 1-8, wherein naloxone is present in the form of naloxone hydrochloride.
12. The oral pharmaceutical preparation defined in any one of claims 1-11, wherein the controlled release formulation is a diffusion matrix.
13. The oral pharmaceutical preparation defined in any one of claims 1-11, wherein the controlled release formulation is a substantially non-swellable diffusion matrix.
14. The oral pharmaceutical preparation defined in any one of claims 1-13, wherein the controlled release formulation further comprises a polymer based on ethylcellulose.
15. The oral pharmaceutical preparation defined in any one of claims 1-13, wherein the controlled release formulation further comprises ethylcellulose.
16. The oral pharmaceutical preparation defined in any one of claims 1-15, wherein the controlled release formulation further comprises a fatty alcohol.
17. The oral pharmaceutical preparation defined in claim 16, wherein the fatty alcohol is selected from the group consisting of lauryl, myrestyl, stearyl, cetostearyl, ceryl, cetyl alcohol and mixtures thereof.
18. The oral pharmaceutical preparation defined in any one of claims 1-17, further comprising a filler.
19. The oral pharmaceutical preparation defined in claim 18, wherein the filler is selected from the group consisting of lactose, glucose, saccharose, starch and a hydrolysate thereof, microcrystalline cellulose, cellatose, a sugar alcohol, a polysoluble calcium salt, talcum and mixtures thereof.
20. The oral pharmaceutical preparation defined in claim 18, wherein the filler is lactose monohydrate.
21. The oral pharmaceutical preparation defined in any one of claims 1-20, further comprising a granulating aid.
22. The oral pharmaceutical preparation defined in claim 21, wherein the granulating aid is povidone.
23. The oral pharmaceutical preparation defined in any one of claims 1-22, further comprising a lubricant.
24. The oral pharmaceutical preparation defined in claim 23, wherein the lubricant is selected from the group consisting of highly-disperse silica, talcum, corn starch, magnesium oxide, magnesium stearate, calcium stearate and mixtures thereof.
25. The oral pharmaceutical preparation defined in claim 23, wherein the lubricant is a combination of talcum and magnesium stearate.
26. The oral pharmaceutical preparation defined in any one of claims 1-25, in the form of a tablet.
27. The oral pharmaceutical preparation defined in any one of claims 1-25, in the form of a multi-layer tablet.
28. The oral pharmaceutical preparation defined in any one of claims 1-25, in the form of a capsule.
29. The oral pharmaceutical preparation defined in any one of claims 1-28, wherein the preparation releases in vitro from about 1% to about 40% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 15 minutes.
30. The oral pharmaceutical preparation defined in any one of claims 1-28, wherein the preparation releases in vitro from about 1% to about 40% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 15 minutes.
31. The oral pharmaceutical preparation defined in any one of claims 1-28, wherein the preparation releases in vitro from about 5% to about 35% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 15 minutes.
32. The oral pharmaceutical preparation defined in any one of claims 1-28, wherein the preparation releases in vitro from about 5% to about 35% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 15 minutes.
33. The oral pharmaceutical preparation defined in any one of claims 1-28, wherein the preparation releases in vitro from about 10% to about 30% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 15 minutes.
34. The oral pharmaceutical preparation defined in any one of claims 1-28, wherein the preparation releases in vitro from about 10% to about 30% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 15 minutes.
35. The oral pharmaceutical preparation defined in any one of claims 1-28, wherein the preparation releases in vitro from about 15% to about 25% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 15 minutes.
36. The oral pharmaceutical preparation defined in any one of claims 1-28, wherein the preparation releases in vitro from about 15% to about 25% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 15 minutes.
37. The oral pharmaceutical preparation defined in any one of claims 1-36, wherein the preparation releases in vitro from about 25% to about 65% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 1 hour.
38. The oral pharmaceutical preparation defined in any one of claims 1-36, wherein the preparation releases in vitro from about 25% to about 65% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 1 hour.
39. The oral pharmaceutical preparation defined in any one of claims 1-36, wherein the preparation releases in vitro from about 30% to about 60% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 1 hour.
40. The oral pharmaceutical preparation defined in any one of claims 1-36, wherein the preparation releases in vitro from about 30% to about 60% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 1 hour.
41. The oral pharmaceutical preparation defined in any one of claims 1-36, wherein the preparation releases in vitro from about 35% to about 55% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 1 hour.
42. The oral pharmaceutical preparation defined in any one of claims 1-36, wherein the preparation releases in vitro from about 35% to about 55% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 1 hour.
43. The oral pharmaceutical preparation defined in any one of claims 1-36, wherein the preparation releases in vitro from about 40% to about 50% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 1 hour.
44. The oral pharmaceutical preparation defined in any one of claims 1-36, wherein the preparation releases in vitro from about 40% to about 50% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 1 hour.
45. The oral pharmaceutical preparation defined in any one of claims 1-44, wherein the preparation releases in vitro from about 40% to about 80% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 2 hours.
46. The oral pharmaceutical preparation defined in any one of claims 1-44, wherein the preparation releases in vitro from about 40% to about 80% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 2 hours.
47. The oral pharmaceutical preparation defined in any one of claims 1-44, wherein the preparation releases in vitro from about 45% to about 75% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 2 hours.
48. The oral pharmaceutical preparation defined in any one of claims 1-44, wherein the preparation releases in vitro from about 45% to about 75% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 2 hours.
49. The oral pharmaceutical preparation defined in any one of claims 1-44, wherein the preparation releases in vitro from about 45% to about 70% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 2 hours.
50. The oral pharmaceutical preparation defined in any one of claims 1-44, wherein the preparation releases in vitro from about 45% to about 70% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 2 hours.
51. The oral pharmaceutical preparation defined in any one of claims 1-50, wherein the preparation releases in vitro from about 70% to 100% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 4 hours.
52. The oral pharmaceutical preparation defined in any one of claims 1-50, wherein the preparation releases in vitro from about 70% to 100% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 4 hours.
53. The oral pharmaceutical preparation defined in any one of claims 1-50, wherein the preparation releases in vitro from about 75% to about 95% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 4 hours.
54. The oral pharmaceutical preparation defined in any one of claims 1-50, wherein the preparation releases in vitro from about 75% to about 95% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 4 hours.
55. The oral pharmaceutical preparation defined in any one of claims 1-50, wherein the preparation releases in vitro from about 80% to about 95% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 4 hours.
56. The oral pharmaceutical preparation defined in any one of claims 1-50, wherein the preparation releases in vitro from about 80% to about 95% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 4 hours.
57. The oral pharmaceutical preparation defined in any one of claims 1-50, wherein the preparation releases in vitro from about 80% to about 90% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 4 hours.
58. The oral pharmaceutical preparation defined in any one of claims 1-50, wherein the preparation releases in vitro from about 80% to about 90% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 4 hours.
59. The oral pharmaceutical preparation defined in any one of claims 1-58, wherein the preparation releases in vitro from about 70% to 100% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 7 hours.
60. The oral pharmaceutical preparation defined in any one of claims 1-58, wherein the preparation releases in vitro from about 70% to 100% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 7 hours.
61. The oral pharmaceutical preparation defined in any one of claims 1-58, wherein the preparation releases in vitro from about 75% to 100% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 7 hours.
62. The oral pharmaceutical preparation defined in any one of claims 1-58, wherein the preparation releases in vitro from about 75% to 100% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 7 hours.
63. The oral pharmaceutical preparation defined in any one of claims 1-58, wherein the preparation releases in vitro from about 80% to about 95% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 7 hours.
64. The oral pharmaceutical preparation defined in any one of claims 1-58, wherein the preparation releases in vitro from about 80% to about 95% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 7 hours.
65. The oral pharmaceutical preparation defined in any one of claims 1-64, wherein the preparation releases in vitro from about 85% to 100% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 12 hours.
66. The oral pharmaceutical preparation defined in any one of claims 1-64, wherein the preparation releases in vitro from about 85% to 100% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 12 hours.
67. The oral pharmaceutical preparation defined in any one of claims 1-64, wherein the preparation releases in vitro from about 90% to 100% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 12 hours.
68. The oral pharmaceutical preparation defined in any one of claims 1-64, wherein the preparation releases in vitro from about 90% to 100% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 12 hours.
69. The oral pharmaceutical preparation defined in any one of claims 1-64, wherein the preparation releases in vitro from about 95% to 100% of at least one of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 12 hours.
70. The oral pharmaceutical preparation defined in any one of claims 1-64, wherein the preparation releases in vitro from about 95% to 100% of both of oxycodone or its pharmaceutically acceptable salt and naloxone or its pharmaceutically acceptable salt at 12 hours.
71. The oral pharmaceutical preparation defined in any one of claims 1-28, wherein release of both of (i) and (ii) is in vitro release determined at pH 1.2 or pH
6.5 using the Basket Method according to the USP with HPLC.
6.5 using the Basket Method according to the USP with HPLC.
72. The oral pharmaceutical preparation defined in any one of claims 1-28, wherein release of both of (i) and (ii) is in vitro release determined at pH 1.2 and pH 6.5 using the Basket Method according to the USP with HPLC.
73. The oral pharmaceutical preparation defined in any one of claims 29-70, wherein in vitro release from the preparation is determined at pH 1.2 or pH 6.5 using the Basket Method according to the USP with HPLC.
74. The oral pharmaceutical preparation defined in any one of claims 29-70, wherein in vitro release from the preparation is determined at pH 1.2 and pH 6.5 using the Basket Method according to the USP with HPLC.
75. The oral pharmaceutical preparation defined in any one of claims 1-74, wherein release of (i) and (ii) from the preparation occurs in a pH independent manner.
76. Use of the oral pharmaceutical preparation defined in any one of claims 1-75 for the treatment of pain.
77. Use of the oral pharmaceutical preparation defined in any one of claims 1-75 for the treatment of severe pain.
78. Use of the oral pharmaceutical preparation defined in any one of claims 1-75 for reducing the occurrence of constipation.
79. Use of the oral pharmaceutical preparation defined in any one of claims 1-75 for reducing the occurrence of obstipation.
80. Use of the oral pharmaceutical preparation defined in any one of claims 1-75 for the treatment of pain and reducing the occurrence of constipation.
81. Use of the oral pharmaceutical preparation defined in any one of claims 1-75 for the treatment of pain and reducing the occurrence of obstipation.
82. Use of the oral pharmaceutical preparation defined in any one of claims 1-75 for the treatment of severe pain and reducing the occurrence of constipation.
83. Use of the oral pharmaceutical preparation defined in any one of claims 1-75 for the treatment of severe pain and reducing the occurrence of obstipation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2708900A CA2708900C (en) | 2002-04-05 | 2003-04-04 | Pharmaceutical preparation containing oxycodone and naloxone |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10215067.2 | 2002-04-05 | ||
DE10215131.8 | 2002-04-05 | ||
DE10215067A DE10215067A1 (en) | 2002-04-05 | 2002-04-05 | Stable pharmaceutical preparation useful for the treatment of pain, especially severe pain, without causing side-effects comprises oxycodone and naxolone in retarded release formulation |
DE10215131A DE10215131A1 (en) | 2002-04-05 | 2002-04-05 | Stable pharmaceutical preparation useful for the treatment of pain, especially severe pain, without causing side-effects comprises oxycodone and naxolone in retarded release formulation |
PCT/EP2003/003540 WO2003084520A2 (en) | 2002-04-05 | 2003-04-04 | Pharmaceutical preparation containing oxycodone and naloxone |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2708900A Division CA2708900C (en) | 2002-04-05 | 2003-04-04 | Pharmaceutical preparation containing oxycodone and naloxone |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2478515A1 CA2478515A1 (en) | 2003-10-16 |
CA2478515C true CA2478515C (en) | 2010-09-28 |
Family
ID=28676052
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2708900A Expired - Fee Related CA2708900C (en) | 2002-04-05 | 2003-04-04 | Pharmaceutical preparation containing oxycodone and naloxone |
CA002478523A Abandoned CA2478523A1 (en) | 2002-04-05 | 2003-04-04 | Matrix for sustained, invariant and independent release of active compounds |
CA2478515A Expired - Lifetime CA2478515C (en) | 2002-04-05 | 2003-04-04 | Pharmaceutical preparation containing oxycodone and naloxone |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2708900A Expired - Fee Related CA2708900C (en) | 2002-04-05 | 2003-04-04 | Pharmaceutical preparation containing oxycodone and naloxone |
CA002478523A Abandoned CA2478523A1 (en) | 2002-04-05 | 2003-04-04 | Matrix for sustained, invariant and independent release of active compounds |
Country Status (33)
Country | Link |
---|---|
US (11) | US20050245483A1 (en) |
EP (17) | EP2311438A1 (en) |
JP (5) | JP4755810B2 (en) |
KR (3) | KR100717591B1 (en) |
CN (4) | CN107669681A (en) |
AP (2) | AP2397A (en) |
AR (3) | AR039378A1 (en) |
AT (1) | ATE418967T2 (en) |
AU (2) | AU2003224041B2 (en) |
BR (2) | BR0309004A (en) |
CA (3) | CA2708900C (en) |
CO (2) | CO5611100A2 (en) |
CY (5) | CY1108914T1 (en) |
DE (6) | DE17169621T1 (en) |
DK (6) | DK1492506T4 (en) |
ES (7) | ES2733051T1 (en) |
FI (1) | FI7846U1 (en) |
GE (3) | GEP20084485B (en) |
HK (5) | HK1072366A1 (en) |
HU (4) | HUE032656T2 (en) |
IL (5) | IL163990A0 (en) |
LT (3) | LT2425821T (en) |
MA (2) | MA27249A1 (en) |
MX (2) | MXPA04009713A (en) |
NZ (1) | NZ535286A (en) |
PH (1) | PH12018000176A1 (en) |
PT (5) | PT1492506E (en) |
RU (3) | RU2295344C2 (en) |
SI (5) | SI2425824T1 (en) |
TN (1) | TNSN04192A1 (en) |
TW (3) | TWI334779B (en) |
WO (2) | WO2003084504A2 (en) |
ZA (2) | ZA200407267B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8518925B2 (en) | 2004-06-08 | 2013-08-27 | Euro-Celtique S.A. | Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) |
US8673355B2 (en) | 1997-12-22 | 2014-03-18 | Purdue Pharma L.P. | Opioid agonist/antagonist combinations |
US8822487B2 (en) | 1997-12-22 | 2014-09-02 | Purdue Pharma L.P. | Opioid agonist/opioid antagonist/acetaminophen combinations |
US8846090B2 (en) | 2002-04-05 | 2014-09-30 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
US8969369B2 (en) | 2001-05-11 | 2015-03-03 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9271940B2 (en) | 2009-03-10 | 2016-03-01 | Purdue Pharma L.P. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
Families Citing this family (133)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
EP2269587A1 (en) | 1999-10-29 | 2011-01-05 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
HUP0204163A2 (en) | 2000-02-08 | 2003-04-28 | Euro-Celtique S.A. | Controlled-release composition containing opioid agonist and antagonist and process for its preparation |
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
AU2738302A (en) | 2000-10-30 | 2002-05-15 | Euro Celtique Sa | Controlled release hydrocodone formulations |
US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
PT1416842E (en) | 2001-07-18 | 2009-03-31 | Euro Celtique Sa | Pharmaceutical combinations of oxycodone and naloxone |
PL367427A1 (en) | 2001-08-06 | 2005-02-21 | Euro-Celtique S.A. | Opioid agonist formulations with releasable and sequestered antagonist |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
PA8578501A1 (en) | 2002-07-25 | 2005-02-04 | Pharmacia Corp | DOSAGE FORM ONCE A DAY OF PRAMIPEXOL |
TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
DE602004026604D1 (en) * | 2003-09-25 | 2010-05-27 | Euro Celtique Sa | PHARMACEUTICAL COMBINATIONS OF HYDROCODON AND NALTREXONE |
GB0403098D0 (en) | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Extrusion |
GB0501638D0 (en) * | 2005-01-28 | 2005-03-02 | Euro Celtique Sa | Particulates |
TWI350762B (en) * | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
EP1604667A1 (en) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the restless leg syndrome |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
MX2007001850A (en) | 2004-08-13 | 2007-03-28 | Boehringer Ingelheim Int | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof. |
KR101406767B1 (en) | 2004-08-13 | 2014-06-20 | 베링거 인겔하임 인터내셔날 게엠베하 | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
MX2007009162A (en) * | 2005-01-28 | 2007-10-23 | Euro Celtique Sa | Alcohol resistant dosage forms. |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
EP1695700A1 (en) | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
EP1810678A1 (en) | 2006-01-19 | 2007-07-25 | Holger Lars Hermann | Use of morphine and naloxone for drug substitution |
AU2011202866B2 (en) * | 2006-01-27 | 2012-06-14 | Mundipharma Pty Limited | Tamper resistant dosage forms |
EP1813276A1 (en) * | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Tamper resistant dosage forms |
US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
DE202006018609U1 (en) * | 2006-08-29 | 2007-05-16 | Euro-Celtique S.A. | Needle-free apparatus for administrating pharmaceutical composition in humans, comprises a housing; auxiliary substance to force a pharmaceutical composition from a package into human body; a composition comprising analgesic, e.g. opioids |
EP1897543A1 (en) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
US20080171762A1 (en) * | 2007-01-16 | 2008-07-17 | Ockert David M | Treatment of pain with naloxone |
DE102007011485A1 (en) * | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Dosage form with more difficult abuse |
CN101801350A (en) * | 2007-08-13 | 2010-08-11 | 阿巴斯迪特宁医药有限公司 | Abuse resistant drugs, using method and preparation method |
RU2007137044A (en) * | 2007-10-05 | 2009-04-10 | Общество С Ограниченной Ответственностью "Концерн О3" (Ru) | HEMOPOESITIMULATING AND HEPATOPROTECTIVE ACTION MEDICINES |
CA2644179C (en) * | 2007-11-21 | 2018-09-25 | Pharmascience Inc. | Novel pharmaceutical composition comprising a disintegration matrix |
US8383152B2 (en) | 2008-01-25 | 2013-02-26 | Gruenenthal Gmbh | Pharmaceutical dosage form |
HUE030803T2 (en) | 2008-05-09 | 2017-06-28 | Gruenenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
WO2010003963A1 (en) * | 2008-07-07 | 2010-01-14 | Euro-Celtique S.A. | Use of opioid antagonists for treating urinary retention |
MX2011001864A (en) | 2008-08-20 | 2011-06-20 | Univ Texas | Hot-melt extrusion of modified release multi-particulates. |
NZ592437A (en) | 2008-10-30 | 2013-03-28 | Gruenenthal Chemie | A dosage form comprising tapentadol and an opioid antagonist |
BRPI0923836A2 (en) | 2008-12-31 | 2015-07-21 | Upsher Smith Lab Inc | Opioid-containing oral pharmaceutical compositions and methods |
GB0909680D0 (en) | 2009-06-05 | 2009-07-22 | Euro Celtique Sa | Dosage form |
RU2555531C2 (en) | 2009-07-22 | 2015-07-10 | Грюненталь Гмбх | Misuse protected dosage form for oxidation sensitive opioids |
KR101738369B1 (en) * | 2009-07-22 | 2017-05-22 | 그뤼넨탈 게엠베하 | Hot-melt extruded controlled release dosage form |
US9023390B2 (en) | 2009-09-17 | 2015-05-05 | Upsher-Smith Laboratories, Inc. | Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug |
US9125867B2 (en) * | 2010-02-24 | 2015-09-08 | Invincible Biotechnology | Diversion- and/or abuse-resistant compositions and methods for making the same |
NZ700732A (en) | 2010-05-10 | 2015-08-28 | Euro Celtique Sa | Pharmaceutical compositions comprising hydromorphone and naloxone |
WO2011141489A1 (en) | 2010-05-10 | 2011-11-17 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
EP2568965A1 (en) | 2010-05-10 | 2013-03-20 | Euro-Celtique S.A. | Combination of active loaded granules with additional actives |
EP2568977A1 (en) | 2010-05-11 | 2013-03-20 | Cima Labs Inc. | Alcohol-resistant metoprolol-containing extended- release oral dosage forms |
CN103124559B (en) | 2010-08-04 | 2017-03-29 | 托马斯·朱利叶斯·波洛迪 | For the device of the compositionss and its preparation and application and delivering said composition of faecal microbiota implantation |
RU2572695C2 (en) * | 2010-08-13 | 2016-01-20 | Эро-Селтик С.А. | Application of binding agents to obtain stable in storage compositions |
EP2611426B1 (en) | 2010-09-02 | 2014-06-25 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
AR082862A1 (en) | 2010-09-02 | 2013-01-16 | Gruenenthal Gmbh | ALTERATION RESISTANT DOSAGE FORM INCLUDING AN ANIONIC POLYMER |
ES2562643T5 (en) * | 2010-09-30 | 2019-05-24 | Astrazeneca Ab | Crystal naloxol-peg conjugate |
AU2011342368B2 (en) | 2010-12-13 | 2016-11-17 | Rite-Prep Pty Ltd | Gastric and colonic formulations and methods for making and using them |
EP4129312A1 (en) | 2011-03-09 | 2023-02-08 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
AT511581A1 (en) | 2011-05-26 | 2012-12-15 | G L Pharma Gmbh | ORAL RETARDANT FORMULATION |
AR087359A1 (en) | 2011-07-29 | 2014-03-19 | Gruenenthal Gmbh | TEST ALTERATION TABLET PROVIDING IMMEDIATE RELEASE OF THE PHARMACO |
EA201400172A1 (en) | 2011-07-29 | 2014-06-30 | Грюненталь Гмбх | SUSTAINABLE TO DESTRUCTION TABLET THAT PROVIDES IMMEDIATE RELEASE OF MEDICINES |
CN103764370B (en) * | 2011-08-29 | 2017-01-18 | 爱克斯普乐器械有限公司 | laboratory extruder |
KR20140075704A (en) | 2011-10-06 | 2014-06-19 | 그뤼넨탈 게엠베하 | Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist |
EA201400590A1 (en) | 2011-11-17 | 2014-11-28 | Грюненталь Гмбх | Resistance to fracture an oral pharmaceutical dosage form comprising a pharmacologically active ingredient opioid antagonist and / or a means, is disgusting, polyalkylene oxide and anionic polymers |
EP2819656A1 (en) | 2012-02-28 | 2015-01-07 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
TW201811332A (en) | 2012-04-17 | 2018-04-01 | 美商普渡製藥有限合夥事業 | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
MX362357B (en) | 2012-04-18 | 2019-01-14 | Gruenenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form. |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
WO2013176774A1 (en) | 2012-05-25 | 2013-11-28 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
CN110170050A (en) | 2012-06-04 | 2019-08-27 | 高拉夫·阿格拉沃尔 | For treating the composition and method of Crohn's disease and related conditions and infection |
PL2877163T3 (en) | 2012-07-27 | 2019-08-30 | Redhill Biopharma Ltd. | Formulations and methods of manufacturing formulations for use in colonic evacuation |
US10485798B2 (en) | 2012-08-22 | 2019-11-26 | Aptapharma Inc. | Methylnaltrexone nasal formulations, methods of making, and use thereof |
MX2015007518A (en) * | 2012-12-14 | 2016-03-01 | Trevi Therapeutics Inc | Methods for treating pruritus. |
WO2014146093A2 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
AU2014262125B2 (en) | 2013-04-30 | 2020-02-13 | Thomas Julius Borody | Compositions and methods for treating microbiota-related psychotropic conditions and diseases |
AU2014270109B2 (en) | 2013-05-24 | 2017-05-25 | Rhodes Technologies | Opioid ketal compounds and uses thereof |
JP6445537B2 (en) | 2013-05-29 | 2018-12-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Tamper-resistant dosage forms containing one or more particles |
AR096439A1 (en) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | DOSAGE METHOD RESISTING TO INDEED USE CONTAINING ONE OR MORE PARTICLES |
EA032465B1 (en) | 2013-07-12 | 2019-05-31 | Грюненталь Гмбх | Tamper-resistant oral pharmaceutical dosage form containing ethylene-vinyl acetate polymer and process for the production thereof |
KR20180037074A (en) | 2013-07-23 | 2018-04-10 | 유로-셀티큐 에스.에이. | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
US10195153B2 (en) | 2013-08-12 | 2019-02-05 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US20150118300A1 (en) | 2013-10-31 | 2015-04-30 | Cima Labs Inc. | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
NZ719087A (en) | 2013-11-13 | 2017-12-22 | Euro Celtique Sa | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
AU2014356581C1 (en) | 2013-11-26 | 2020-05-28 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
WO2015086528A1 (en) | 2013-12-11 | 2015-06-18 | Develco Pharma Schweiz Ag | Naloxone mono-product and multi-layer tablet |
US10105360B2 (en) | 2013-12-11 | 2018-10-23 | Develco Pharma Schweiz Ag | Method and composition for the treatment of opioid induced constipation |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
WO2015095644A1 (en) | 2013-12-20 | 2015-06-25 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
US9480644B2 (en) | 2014-03-14 | 2016-11-01 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
SG10202003562WA (en) | 2014-03-14 | 2020-05-28 | Opiant Pharmaceuticals Inc | Nasal drug products and methods of their use |
US10085937B2 (en) | 2014-03-14 | 2018-10-02 | Adapt Pharma Limited | Nasal drug products and methods of their use |
US9561177B2 (en) | 2014-03-14 | 2017-02-07 | Adapt Pharma Limited | Nasal drug products and methods of their use |
AU2015261060A1 (en) | 2014-05-12 | 2016-11-03 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising Tapentadol |
CA2949422A1 (en) | 2014-05-26 | 2015-12-03 | Grunenthal Gmbh | Multiparticles safeguarded against ethanolic dose-dumping |
EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
EP3229785A2 (en) * | 2014-12-08 | 2017-10-18 | Develco Pharma Schweiz AG | Naloxone monopreparation and multi-layer tablet |
EP3285745A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
WO2016183577A1 (en) | 2015-05-14 | 2016-11-17 | Crestovo Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
PL3297644T3 (en) | 2015-05-22 | 2022-05-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
JP2018526414A (en) | 2015-09-10 | 2018-09-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Protection against oral overdose with abuse-inhibiting immediate release formulations |
US11214773B2 (en) | 2015-09-24 | 2022-01-04 | San Diego State University (Sdsu) Foundation | Antibacterial and protective bacteriophage formulations and methods for making and using them |
US9861629B1 (en) | 2015-10-07 | 2018-01-09 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
AU2017241266B2 (en) * | 2016-03-31 | 2022-02-10 | SpecGx LLC | Extended release, abuse deterrent dosage forms |
US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
EP3290027A1 (en) * | 2016-09-02 | 2018-03-07 | Develco Pharma Schweiz AG | Method and composition for the treatment of opioid induced constipation |
WO2018071537A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
CA3058818A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating parkinson's disease (pd) and related disorders |
US11040073B2 (en) | 2017-04-05 | 2021-06-22 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
US11890306B2 (en) | 2017-05-26 | 2024-02-06 | Finch Therapeutics Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
JP2020530494A (en) | 2017-08-07 | 2020-10-22 | フィンチ セラピューティクス、インコーポレイテッド. | Compositions and Methods for Maintaining and Restoring a Healthy Intestinal Barrier |
US10624856B2 (en) | 2018-01-31 | 2020-04-21 | Dharma Laboratories LLC | Non-extractable oral solid dosage forms |
WO2019152002A1 (en) * | 2018-01-31 | 2019-08-08 | Dharma Laboratories LLC | Non-extractable oral solid dosage forms |
US11845759B2 (en) | 2018-02-23 | 2023-12-19 | Rhodes Technologies | Opioid compounds and uses thereof |
US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
SG11202100580UA (en) | 2018-07-23 | 2021-02-25 | Trevi Therapeutics Inc | Treatment of chronic cough, breathlessness and dyspnea |
AU2019351017A1 (en) | 2018-09-27 | 2021-04-29 | Finch Therapeutics Holdings Llc. | Compositions and methods for treating epilepsy and related disorders |
WO2020225773A1 (en) | 2019-05-07 | 2020-11-12 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
Family Cites Families (278)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2770569A (en) | 1952-08-01 | 1956-11-13 | Hoffmann La Roche | Analgesic compositions |
US3173877A (en) | 1957-09-09 | 1965-03-16 | Wyandotte Chemicals Corp | Detergent compositions comprising inorganic esters of epoxyhydrocarbon polymers |
US3173876A (en) * | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
NL271831A (en) * | 1960-11-29 | |||
US3493657A (en) | 1961-03-14 | 1970-02-03 | Mozes Juda Lewenstein | Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine |
US3332950A (en) | 1963-03-23 | 1967-07-25 | Endo Lab | 14-hydroxydihydronormorphinone derivatives |
US3276586A (en) * | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
NL6714885A (en) * | 1967-11-02 | 1969-05-06 | ||
US3541006A (en) * | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
US3541005A (en) * | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
US3773955A (en) | 1970-08-03 | 1973-11-20 | Bristol Myers Co | Analgetic compositions |
US3879555A (en) | 1970-11-16 | 1975-04-22 | Bristol Myers Co | Method of treating drug addicts |
US3676557A (en) | 1971-03-02 | 1972-07-11 | Endo Lab | Long-acting narcotic antagonist formulations |
GB1390772A (en) * | 1971-05-07 | 1975-04-16 | Endo Lab | Oral narcotic composition |
FR2183546B1 (en) * | 1972-05-10 | 1975-06-20 | Servier Lab | |
US3965256A (en) | 1972-05-16 | 1976-06-22 | Synergistics | Slow release pharmaceutical compositions |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3916889A (en) * | 1973-09-28 | 1975-11-04 | Sandoz Ag | Patient ventilator apparatus |
US3966940A (en) | 1973-11-09 | 1976-06-29 | Bristol-Myers Company | Analgetic compositions |
GB1478759A (en) * | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
US3966040A (en) * | 1975-03-05 | 1976-06-29 | Hazelwood John E | Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator |
US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4126684A (en) * | 1976-02-11 | 1978-11-21 | Ciba-Geigy Corporation | 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse |
US4063064A (en) * | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
LU77339A1 (en) | 1977-05-16 | 1979-01-19 | ||
US4176186A (en) | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
US4237140A (en) | 1979-05-18 | 1980-12-02 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and acetaminophen |
US4293539A (en) | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
IE49324B1 (en) | 1979-12-19 | 1985-09-18 | Euro Celtique Sa | Controlled release compositions |
US4457933A (en) * | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
US4401672A (en) | 1981-10-13 | 1983-08-30 | Regents Of The University Of Minnesota | Non-addictive narcotic antitussive preparation |
US4608376A (en) | 1981-10-16 | 1986-08-26 | Carolyn McGinnis | Opiate agonists and antagonists |
US4987136A (en) | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
JPS59500418A (en) * | 1982-03-16 | 1984-03-15 | ザ ロツクフエラ− ユニバ−シテイ | How to recover from gastrointestinal dysfunction |
US4443428A (en) | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
US4451470A (en) | 1982-07-06 | 1984-05-29 | E. I. Du Pont De Nemours And Company | Analgesic, antagonist, and/or anorectic 14-fluoromorphinans |
US4803208A (en) | 1982-09-30 | 1989-02-07 | Sloan-Kettering Institute For Cancer Research | Opiate agonists and antagonists |
GB8332556D0 (en) | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US5266574A (en) | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
US4668685A (en) * | 1984-07-05 | 1987-05-26 | E.I. Du Pont De Nemours And Company | Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists |
US4626539A (en) * | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
DE3434946A1 (en) | 1984-09-22 | 1986-04-03 | Basf Ag, 6700 Ludwigshafen | DIARYLACETYLENE, THEIR PRODUCTION AND USE |
US4573995A (en) | 1984-10-09 | 1986-03-04 | Alza Corporation | Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine |
GB8430346D0 (en) | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
CA1267092A (en) | 1985-02-25 | 1990-03-27 | Martin D. Hynes | Analgesic composition containing codeine |
JPS61280423A (en) | 1985-06-05 | 1986-12-11 | Kiyuukiyuu Yakuhin Kogyo Kk | Mucosal application agent in oral cavity |
GB8514665D0 (en) | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
FR2585246A1 (en) | 1985-07-26 | 1987-01-30 | Cortial | PROCESS FOR OBTAINING SOLID PHARMACEUTICAL FORMS WITH PROLONGED RELEASE |
GB8521350D0 (en) | 1985-08-28 | 1985-10-02 | Euro Celtique Sa | Analgesic composition |
DE3690457T1 (en) | 1985-09-06 | 1987-08-06 | ||
US4889860A (en) | 1985-09-23 | 1989-12-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
US4760069A (en) | 1985-09-23 | 1988-07-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
US4722928A (en) | 1985-12-02 | 1988-02-02 | E. I. Du Pont De Nemours And Company | N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes |
US4730048A (en) | 1985-12-12 | 1988-03-08 | Regents Of The University Of Minnesota | Gut-selective opiates |
US4719215A (en) | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US4861781A (en) | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US5316759A (en) | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
GB8613688D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
ES2058111T3 (en) | 1986-06-10 | 1994-11-01 | Euro Celtique Sa | COMPOSITION OF CONTROLLED RELEASE OF DIHYDROCODEIN. |
US4785000A (en) | 1986-06-18 | 1988-11-15 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4769372A (en) | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4970075A (en) | 1986-07-18 | 1990-11-13 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US4861598A (en) * | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US5356900A (en) | 1986-10-07 | 1994-10-18 | Bernard Bihari | Method of treating chronic herpes virus infections using an opiate receptor antagonist |
GB8626098D0 (en) | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
US4806543A (en) | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
GB8628728D0 (en) | 1986-12-02 | 1987-01-07 | Euro Celtique Sa | Spheroids |
GB8705083D0 (en) | 1987-03-04 | 1987-04-08 | Euro Celtique Sa | Spheroids |
GB8728294D0 (en) | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
DE3812567A1 (en) * | 1988-04-15 | 1989-10-26 | Basf Ag | METHOD FOR PRODUCING PHARMACEUTICAL MIXTURES |
US4873076A (en) | 1988-04-29 | 1989-10-10 | Baker Cummins Pharmaceuticals, Inc. | Method of safely providing anesthesia or conscious sedation |
GB8813064D0 (en) | 1988-06-02 | 1988-07-06 | Euro Celtique Sa | Controlled release dosage forms having defined water content |
US4882335A (en) | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
EP0352361A1 (en) | 1988-07-29 | 1990-01-31 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US5236714A (en) | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
CA2002492A1 (en) | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
US5102887A (en) | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
US5096715A (en) | 1989-11-20 | 1992-03-17 | Alko Ltd. | Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist |
US5075341A (en) | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
US5086058A (en) | 1990-06-04 | 1992-02-04 | Alko Ltd. | Method for treating alcoholism with nalmefene |
FR2669336B1 (en) | 1990-11-20 | 1993-01-22 | Adir | NOVEL OXAZOLO PYRIDINES DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
HU208633B (en) | 1991-02-04 | 1993-12-28 | Alkaloida Vegyeszeti Gyar | Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression |
US5486362A (en) | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
JP3178541B2 (en) | 1991-05-29 | 2001-06-18 | キヤノン株式会社 | Image processing method and apparatus |
US5149538A (en) | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
GB9117361D0 (en) * | 1991-08-12 | 1991-09-25 | Euro Celtique Sa | Oral dosage form |
KR100221695B1 (en) * | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | Pharmaceutical spheroid formulation |
DK0566709T5 (en) | 1991-09-06 | 2009-05-18 | Ortho Mcneil Janssen Pharm | Composition containing a tramadol material and acetaminophen and use thereof |
US5215758A (en) | 1991-09-11 | 1993-06-01 | Euroceltique, S.A. | Controlled release matrix suppository for pharmaceuticals |
US5225440A (en) | 1991-09-13 | 1993-07-06 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase |
US5656295A (en) * | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5273760A (en) * | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5681585A (en) * | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5958459A (en) | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
GB9203689D0 (en) | 1992-02-20 | 1992-04-08 | Euro Celtique Sa | Pharmaceutical composition |
GB9204354D0 (en) | 1992-02-28 | 1992-04-08 | Biokine Tech Ltd | Compounds for medicinal use |
CA2138026C (en) | 1992-06-22 | 2003-09-09 | Eckard Weber | Novel 1,4-dihydroquinoxaline-2,3-diones and uses therefor as glycine receptor antagonists |
US5352680A (en) | 1992-07-15 | 1994-10-04 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists to block opioid agonist tolerance and dependence |
US5256669A (en) | 1992-08-07 | 1993-10-26 | Aminotek Sciences, Inc. | Methods and compositions for treating acute or chronic pain and drug addiction |
US5324351A (en) * | 1992-08-13 | 1994-06-28 | Euroceltique | Aqueous dispersions of zein and preparation thereof |
US5633259A (en) | 1992-09-21 | 1997-05-27 | United Biomedical, Inc. | Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction |
US6096756A (en) | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5580876A (en) | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
WO1994006426A1 (en) | 1992-09-21 | 1994-03-31 | Qin Bo Yi | Methods for identifying and using low/non-addictive opioid analgesics |
US20010006967A1 (en) | 1992-09-21 | 2001-07-05 | Stanley M. Crain | Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists |
US5512578A (en) | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
US5472943A (en) | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
US5869097A (en) | 1992-11-02 | 1999-02-09 | Alza Corporation | Method of therapy comprising an osmotic caplet |
US5604260A (en) | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
US5585348A (en) | 1993-02-10 | 1996-12-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia |
US5352683A (en) | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
CA2115792C (en) | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
US5409944A (en) | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
IL119660A (en) | 1993-05-10 | 2002-09-12 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5436265A (en) | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
CN1230154C (en) * | 1993-07-01 | 2005-12-07 | 欧洲凯尔特公司 | Sustained release compositions and a method of preparing pharmaceutical compositions |
NZ260883A (en) | 1993-07-01 | 1997-06-24 | Euro Celtique Sa | Oral sustained-release medicaments containing morphine |
US5879705A (en) | 1993-07-27 | 1999-03-09 | Euro-Celtique S.A. | Sustained release compositions of morphine and a method of preparing pharmaceutical compositions |
DE4325465B4 (en) * | 1993-07-29 | 2004-03-04 | Zenz, Michael, Prof. Dr.med. | Oral pharmaceutical preparation for pain therapy |
GB9319568D0 (en) | 1993-09-22 | 1993-11-10 | Euro Celtique Sa | Pharmaceutical compositions and usages |
EP0647448A1 (en) | 1993-10-07 | 1995-04-12 | Euroceltique S.A. | Orally administrable opioid formulations having extended duration of effect |
US6210714B1 (en) | 1993-11-23 | 2001-04-03 | Euro-Celtique S.A. | Immediate release tablet cores of acetaminophen having sustained-release coating |
US5891471A (en) | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
KR100354702B1 (en) | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | Manufacturing method and sustained release composition of pharmaceutical composition |
US5500227A (en) | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
ES2168290T3 (en) | 1993-11-23 | 2002-06-16 | Euro Celtique Sa | METHOD FOR PREPARING A SUSTAINED RELEASE COMPOSITION. |
US5834477A (en) | 1993-12-08 | 1998-11-10 | The United States Of America As Represented By The Secretary Of The Army | Opiate analgesic formulation with improved safety |
US5376662A (en) | 1993-12-08 | 1994-12-27 | Ockert; David M. | Method of attenuating nerve injury induced pain |
US5843480A (en) | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
US6077533A (en) | 1994-05-25 | 2000-06-20 | Purdue Pharma L.P. | Powder-layered oral dosage forms |
US5411745A (en) * | 1994-05-25 | 1995-05-02 | Euro-Celtique, S.A. | Powder-layered morphine sulfate formulations |
US5958458A (en) * | 1994-06-15 | 1999-09-28 | Dumex-Alpharma A/S | Pharmaceutical multiple unit particulate formulation in the form of coated cores |
US5460826A (en) | 1994-06-27 | 1995-10-24 | Alza Corporation | Morphine therapy |
GB9414699D0 (en) | 1994-07-21 | 1994-09-07 | Slagel David | Aqueous foamable composition |
US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5521213A (en) | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5593994A (en) | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
US5866154A (en) * | 1994-10-07 | 1999-02-02 | The Dupont Merck Pharmaceutical Company | Stabilized naloxone formulations |
GB9422154D0 (en) | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
ATE532530T1 (en) | 1994-12-12 | 2011-11-15 | Omeros Corp | FLUSHING SOLUTION AND THE USE THEREOF FOR THE PERIOPERATIVE INHIBITION OF PAIN, INFLAMMATION AND/OR SPASMS IN A VESSEL STRUCTURE |
GB9426102D0 (en) | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Pharmacuetical compositions |
US5692500A (en) | 1995-01-09 | 1997-12-02 | Gaston-Johansson; Fannie | Pain measurement and recording tool and method |
US5552422A (en) | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
US5578725A (en) | 1995-01-30 | 1996-11-26 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
US20020006964A1 (en) * | 1995-05-16 | 2002-01-17 | Young James W. | Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds |
US5510368A (en) | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
US5639780A (en) | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
US5604253A (en) | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
HUP9700322A3 (en) | 1995-06-09 | 2001-03-28 | Euro Celtique Sa | Formulations and methods for providing prolonged local anesthesia |
US5931809A (en) | 1995-07-14 | 1999-08-03 | Depotech Corporation | Epidural administration of therapeutic compounds with sustained rate of release |
GB9517062D0 (en) * | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
GB9517883D0 (en) | 1995-09-01 | 1995-11-01 | Euro Celtique Sa | Improved pharmaceutical ion exchange resin composition |
GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
US5811126A (en) | 1995-10-02 | 1998-09-22 | Euro-Celtique, S.A. | Controlled release matrix for pharmaceuticals |
AUPN603895A0 (en) | 1995-10-19 | 1995-11-09 | University Of Queensland, The | Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids |
WO1997020819A1 (en) | 1995-12-06 | 1997-06-12 | Eli Lilly And Company | Composition for treating pain |
EA001773B1 (en) | 1996-03-08 | 2001-08-27 | Нюкомед Данмарк А/С | Oral pharmaceutical medicament as modified release miltiple units composition |
ES2168610T3 (en) | 1996-03-12 | 2002-06-16 | Alza Corp | COMPOSITION AND GALENIC FORM CONTAINING AN OPIOID ANTAGONIST. |
US6103258A (en) | 1996-04-12 | 2000-08-15 | Simon; David Lew | Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics |
EP0854884A1 (en) * | 1996-04-17 | 1998-07-29 | Neurocrine Biosciences, Inc. | Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor |
WO1997045091A2 (en) * | 1996-05-31 | 1997-12-04 | Euro-Celtique, S.A. | Sustained release oxycodone formulations with no fed/fast effect |
WO1998024412A2 (en) * | 1996-12-05 | 1998-06-11 | The Board Of Trustees Of The University Of Illinois | Compounds useful against diseases of the colon and methods for orally administering same |
DE19651551C2 (en) * | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioid antagonist-containing galenic formulation |
EP0880352B1 (en) | 1997-02-14 | 1999-11-17 | Gödecke Aktiengesellschaft | Stabilization of naloxone hydrochloride |
DE29719704U1 (en) | 1997-02-14 | 1998-01-22 | Goedecke Ag | Stable preparations of naloxone hydrochloride |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
DE19710008A1 (en) | 1997-03-12 | 1998-09-17 | Basf Ag | Solid, at least two-phase formulations of a sustained-release opioid analgesic |
US5780479A (en) | 1997-04-04 | 1998-07-14 | Regents Of The University Of Minnesota | Use of opioid antagonists to treat impulse-control disorders |
US6207142B1 (en) * | 1997-04-14 | 2001-03-27 | Janssen Pharmaceutica N.V. | Compositions containing an antifungal and a cationic agent |
DK1009387T3 (en) | 1997-07-02 | 2006-08-14 | Euro Celtique Sa | Long-release stabilized tramadol formulations |
AU3690297A (en) | 1997-07-30 | 1999-02-22 | Universite De Montreal | Portable and programmable interactive visual analogue scale data-logger device |
DE69823520T2 (en) | 1997-09-04 | 2005-05-12 | Novoneuron, Inc., Miami | NORIBOGAIN FOR THE TREATMENT OF PAIN AND DRUG DEPENDENCE |
US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
US6274591B1 (en) | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
EP0913152B1 (en) | 1997-11-03 | 2001-12-19 | Stada Arzneimittel Ag | Stabilised combination of drugs comprising naloxone and an opioid analgesic |
PT1685839E (en) | 1997-12-22 | 2013-07-08 | Euro Celtique Sa | Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist |
CA2314896C (en) | 1997-12-22 | 2005-09-13 | Euro-Celtique, S.A. | A method of preventing abuse of opioid dosage forms |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
ES2255255T3 (en) * | 1998-03-27 | 2006-06-16 | PHARMACIA & UPJOHN COMPANY LLC | USE OF CABERGOLINE IN THE TREATMENT OF THE UNDERSTANDING LEG SYNDROME. |
US5957459A (en) | 1998-04-27 | 1999-09-28 | Chae; Myung Joo | Banking card game |
DE19857766A1 (en) | 1998-05-28 | 1999-12-02 | Krewel Meuselbach Gmbh | Delayed pain reliever containing tilidine |
EP0960619B1 (en) | 1998-05-28 | 2004-03-10 | Krewel Meuselbach GmbH | Sustained release analgesic compositions comprising tilidine |
DE29818454U1 (en) | 1998-10-15 | 1999-01-14 | Euro Celtique Sa | Opioid analgesic |
SE9803760D0 (en) | 1998-11-04 | 1998-11-04 | Jan Hedner | Methods to treat and diagnose the restless legs syndrome and the corresponding agents |
FR2787715B1 (en) | 1998-12-23 | 2002-05-10 | Synthelabo | PHARMACEUTICAL COMPOSITION COMPRISING A HYPNOTIC COMPOUND OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS |
DE19859636A1 (en) * | 1998-12-23 | 2000-06-29 | Hexal Ag | Controlled release pharmaceutical composition with tilidine mesylate as active ingredient |
DE19901085C2 (en) | 1999-01-14 | 2003-12-18 | Lohmann Therapie Syst Lts | Transdermal therapeutic system with a self-adhesive matrix containing organic acid addition salts of morphine or morphine type alkaloids |
US6194382B1 (en) | 1999-03-03 | 2001-02-27 | Albert Einstein College Of Medicine Of Yeshiva University | Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists |
DE19918325A1 (en) | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives |
US6765010B2 (en) | 1999-05-06 | 2004-07-20 | Pain Therapeutics, Inc. | Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
US20030178031A1 (en) * | 1999-05-07 | 2003-09-25 | Du Pen, Inc. | Method for cancer pain treatment |
US6419595B1 (en) | 1999-07-09 | 2002-07-16 | Bridgestone Sports Co., Ltd. | Solid golf ball |
US20030118641A1 (en) * | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
US6451007B1 (en) | 1999-07-29 | 2002-09-17 | Dale E. Koop | Thermal quenching of tissue |
DE19938823A1 (en) * | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Treatment of restless leg syndrome symptoms, using synergistic combination of alpha-2 agonist, preferably clonidine, and another neuro-psychic drug, e.g. pramipexol |
US6258042B1 (en) * | 1999-09-17 | 2001-07-10 | James S. Factor | Visual analog scale and method of use for the diagnosis and/or treatment of physical pain |
US6451806B2 (en) | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
IL149378A0 (en) | 1999-11-01 | 2002-11-10 | Rodeva Ltd | Composition for treatment of constipation and irritable bowel syndrome |
CA2392362A1 (en) | 1999-11-29 | 2001-05-31 | Adolor Corporation | Novel methods and compositions involving opioids and antagonists thereof |
WO2001052851A1 (en) | 2000-01-22 | 2001-07-26 | Albert Shulman | Methods for the treatment of substance abuse |
HUP0204163A2 (en) * | 2000-02-08 | 2003-04-28 | Euro-Celtique S.A. | Controlled-release composition containing opioid agonist and antagonist and process for its preparation |
US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
EP1263438B1 (en) | 2000-03-15 | 2006-05-17 | Wolfgang Sadee | Neutral antagonists and use thereof in treating drug abuse |
CA2408106A1 (en) | 2000-05-05 | 2001-11-15 | Pain Therapeutics, Inc. | Opioid antagonist compositions and dosage forms |
EP1280529A2 (en) | 2000-05-05 | 2003-02-05 | Pain Therapeutics, Inc. | Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists |
AU2001268353A1 (en) | 2000-06-09 | 2001-12-17 | The Regents Of The University Of California | Method of treating pain using nalbuphine and opioid antagonists |
US7223421B2 (en) * | 2000-06-30 | 2007-05-29 | Mcneil-Ppc, Inc. | Teste masked pharmaceutical particles |
GB0026137D0 (en) | 2000-10-25 | 2000-12-13 | Euro Celtique Sa | Transdermal dosage form |
AR031152A1 (en) * | 2000-10-31 | 2003-09-10 | Upjohn Co | NEW TREATMENTS FOR THE CONCERNED LEG SYNDROME |
NZ528151A (en) * | 2001-04-19 | 2005-04-29 | Warner Lambert Co | Fused bicyclic or tricyclic amino acids |
UA81224C2 (en) | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Dosage form of oxycodone and use thereof |
DE60216078T2 (en) | 2001-05-11 | 2007-07-05 | Endo Pharmaceuticals Inc. | OPIOID CONTAINING ARZNEIFORM AGAINST MISUSE |
US20030065002A1 (en) * | 2001-05-11 | 2003-04-03 | Endo Pharmaceuticals, Inc. | Abuse-resistant controlled-release opioid dosage form |
DE10131113A1 (en) | 2001-06-28 | 2003-01-23 | Siemens Linear Motor Systems G | Rotary electric motor |
US20030021841A1 (en) | 2001-07-02 | 2003-01-30 | Matharu Amol Singh | Pharmaceutical composition |
PT1416842E (en) | 2001-07-18 | 2009-03-31 | Euro Celtique Sa | Pharmaceutical combinations of oxycodone and naloxone |
PL367427A1 (en) | 2001-08-06 | 2005-02-21 | Euro-Celtique S.A. | Opioid agonist formulations with releasable and sequestered antagonist |
US20030044458A1 (en) * | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
CA2455420A1 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique, S.A. | Compositions and methods to prevent abuse of opioids |
CA2456322A1 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique, S.A. | Compositions and methods to prevent abuse of opioids |
US7332182B2 (en) * | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
US20030157168A1 (en) | 2001-08-06 | 2003-08-21 | Christopher Breder | Sequestered antagonist formulations |
US7144587B2 (en) * | 2001-08-06 | 2006-12-05 | Euro-Celtique S.A. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
EP1427476B1 (en) | 2001-09-06 | 2009-03-25 | Hans Gregersen | Apparatus for stimulating a bodily hollow system and for measuring reactions to stimuli of such system |
US20040253310A1 (en) * | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
US20040234602A1 (en) * | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
JP2005512965A (en) * | 2001-09-24 | 2005-05-12 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Anticonvulsant derivatives useful in the treatment of restless limb syndrome and periodic limb movement disorders |
EP1482835B1 (en) | 2002-03-06 | 2012-09-12 | Euro-Celtique S.A. | Analog scale for measuring pain |
IL163911A0 (en) | 2002-03-14 | 2005-12-18 | Euro Celtique Sa | Naltrexone hydrochloride compositions |
SI2425824T1 (en) | 2002-04-05 | 2017-06-30 | Mundipharma Medical Cee Gmbh | Pharmaceutical preparation containing oxycodone and naloxone |
DE10215067A1 (en) | 2002-04-05 | 2003-10-16 | Euro Celtique Sa | Stable pharmaceutical preparation useful for the treatment of pain, especially severe pain, without causing side-effects comprises oxycodone and naxolone in retarded release formulation |
DE10215131A1 (en) | 2002-04-05 | 2003-10-16 | Euro Celtique Sa | Stable pharmaceutical preparation useful for the treatment of pain, especially severe pain, without causing side-effects comprises oxycodone and naxolone in retarded release formulation |
US20030191147A1 (en) * | 2002-04-09 | 2003-10-09 | Barry Sherman | Opioid antagonist compositions and dosage forms |
EP1364649A1 (en) | 2002-05-23 | 2003-11-26 | Cilag AG | Adduct of topiramate and tramadol hydrochioride and uses thereof |
CA2491572C (en) * | 2002-07-05 | 2010-03-23 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
RU2222260C1 (en) | 2002-07-08 | 2004-01-27 | Сибирский государственный медицинский университет | Method for carrying out differential evaluation of functional activity degree of small intestine |
CA2499994C (en) | 2002-09-23 | 2012-07-10 | Verion, Inc. | Abuse-resistant pharmaceutical compositions |
JP2006516969A (en) | 2003-01-23 | 2006-07-13 | アモレパシフィック コーポレーション | Sustained release preparation and method for producing the same |
CN1767831B (en) | 2003-04-08 | 2014-12-10 | 普罗热尼奇制药公司 | Pharmaceutical formulations containing methylnaltrexone |
TWI357815B (en) | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
US20050053659A1 (en) | 2003-09-10 | 2005-03-10 | Pace Gary W. | Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness |
TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
US7700626B2 (en) * | 2004-06-04 | 2010-04-20 | Adolor Corporation | Compositions containing opioid antagonists |
EP1604667A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the restless leg syndrome |
EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
GB2418854B (en) | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
MX2007009162A (en) | 2005-01-28 | 2007-10-23 | Euro Celtique Sa | Alcohol resistant dosage forms. |
EP1695700A1 (en) | 2005-02-28 | 2006-08-30 | Euro-Celtique S.A. | Dosage form containing oxycodone and naloxone |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
US20070092576A1 (en) | 2005-10-20 | 2007-04-26 | Adolor Corporation | Compositions containing opioid antagonists |
EP1813276A1 (en) | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Tamper resistant dosage forms |
US20070185145A1 (en) | 2006-02-03 | 2007-08-09 | Royds Robert B | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same |
WO2007111945A2 (en) | 2006-03-22 | 2007-10-04 | Trustees Of Boston University | Method for management of diarrhea |
MX2008013441A (en) | 2006-04-19 | 2009-02-11 | Jill P Smith | Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists. |
DE202006018609U1 (en) | 2006-08-29 | 2007-05-16 | Euro-Celtique S.A. | Needle-free apparatus for administrating pharmaceutical composition in humans, comprises a housing; auxiliary substance to force a pharmaceutical composition from a package into human body; a composition comprising analgesic, e.g. opioids |
TW200817048A (en) | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
EP2042176A1 (en) | 2007-09-26 | 2009-04-01 | Euro-Celtique S.A. | Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease |
WO2010003963A1 (en) | 2008-07-07 | 2010-01-14 | Euro-Celtique S.A. | Use of opioid antagonists for treating urinary retention |
PL2405915T3 (en) | 2009-03-10 | 2019-05-31 | Euro Celtique Sa | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
NO330672B1 (en) | 2009-11-12 | 2011-06-06 | Proxdynamics As | Rotor mechanism for helicopters |
RU2572695C2 (en) | 2010-08-13 | 2016-01-20 | Эро-Селтик С.А. | Application of binding agents to obtain stable in storage compositions |
-
2003
- 2003-04-04 SI SI200332523A patent/SI2425824T1/en unknown
- 2003-04-04 HU HUE11177516A patent/HUE032656T2/en unknown
- 2003-04-04 JP JP2003581760A patent/JP4755810B2/en not_active Expired - Fee Related
- 2003-04-04 DK DK03720425.2T patent/DK1492506T4/en active
- 2003-04-04 KR KR1020047015830A patent/KR100717591B1/en active IP Right Grant
- 2003-04-04 ES ES17154462T patent/ES2733051T1/en active Pending
- 2003-04-04 ES ES03720425.2T patent/ES2320748T5/en not_active Expired - Lifetime
- 2003-04-04 AU AU2003224041A patent/AU2003224041B2/en not_active Expired
- 2003-04-04 WO PCT/EP2003/003541 patent/WO2003084504A2/en active Application Filing
- 2003-04-04 DE DE17169621.4T patent/DE17169621T1/en active Pending
- 2003-04-04 HU HUE03720424A patent/HUE027004T2/en unknown
- 2003-04-04 EP EP10180494A patent/EP2311438A1/en not_active Withdrawn
- 2003-04-04 SI SI200332524A patent/SI2425821T1/en unknown
- 2003-04-04 PT PT03720425T patent/PT1492506E/en unknown
- 2003-04-04 TW TW092107765A patent/TWI334779B/en not_active IP Right Cessation
- 2003-04-04 EP EP05020580A patent/EP1639997A1/en not_active Withdrawn
- 2003-04-04 DE DE20321531U patent/DE20321531U1/en not_active Expired - Lifetime
- 2003-04-04 EP EP17154462.0A patent/EP3241548A1/en not_active Withdrawn
- 2003-04-04 NZ NZ535286A patent/NZ535286A/en not_active IP Right Cessation
- 2003-04-04 HU HUE11177518A patent/HUE032529T2/en unknown
- 2003-04-04 CA CA2708900A patent/CA2708900C/en not_active Expired - Fee Related
- 2003-04-04 ES ES03720424.5T patent/ES2546010T3/en not_active Expired - Lifetime
- 2003-04-04 GE GEAP8489A patent/GEP20084485B/en unknown
- 2003-04-04 DE DE20308436U patent/DE20308436U1/en not_active Expired - Lifetime
- 2003-04-04 DK DK11177520.1T patent/DK2425825T3/en active
- 2003-04-04 AP APAP/P/2004/003138A patent/AP2397A/en active
- 2003-04-04 PT PT111775169T patent/PT2425824T/en unknown
- 2003-04-04 GE GEAP20038488A patent/GEP20074022B/en unknown
- 2003-04-04 US US10/510,673 patent/US20050245483A1/en not_active Abandoned
- 2003-04-04 TW TW092107773A patent/TWI337077B/en not_active IP Right Cessation
- 2003-04-04 PT PT37204245T patent/PT1492505E/en unknown
- 2003-04-04 EP EP10160827A patent/EP2243471A1/en not_active Withdrawn
- 2003-04-04 BR BR0309004-3A patent/BR0309004A/en not_active Application Discontinuation
- 2003-04-04 KR KR1020067027164A patent/KR100784341B1/en active IP Right Grant
- 2003-04-04 AT AT03720425T patent/ATE418967T2/en active
- 2003-04-04 WO PCT/EP2003/003540 patent/WO2003084520A2/en active Application Filing
- 2003-04-04 ES ES11177520.1T patent/ES2608006T3/en not_active Expired - Lifetime
- 2003-04-04 EP EP11177516.9A patent/EP2425824B1/en not_active Revoked
- 2003-04-04 US US10/510,674 patent/US20050245556A1/en not_active Abandoned
- 2003-04-04 LT LTEP11177518.5T patent/LT2425821T/en unknown
- 2003-04-04 EP EP11177518.5A patent/EP2425821B1/en not_active Revoked
- 2003-04-04 JP JP2003581744A patent/JP4620355B2/en not_active Expired - Fee Related
- 2003-04-04 EP EP03720425.2A patent/EP1492506B2/en not_active Expired - Lifetime
- 2003-04-04 RU RU2004131870/15A patent/RU2295344C2/en active
- 2003-04-04 DK DK11177516.9T patent/DK2425824T5/en active
- 2003-04-04 LT LTEP11177516.9T patent/LT2425824T/en unknown
- 2003-04-04 PT PT111775185T patent/PT2425821T/en unknown
- 2003-04-04 EP EP10176078A patent/EP2308475A1/en not_active Withdrawn
- 2003-04-04 CN CN201710521042.3A patent/CN107669681A/en active Pending
- 2003-04-04 CN CNB038071770A patent/CN100411611C/en not_active Expired - Lifetime
- 2003-04-04 CN CN2012102169087A patent/CN102813654A/en active Pending
- 2003-04-04 EP EP10180495A patent/EP2308474A1/en not_active Withdrawn
- 2003-04-04 GE GEAP8488A patent/GEP20064022B/en unknown
- 2003-04-04 SI SI200332513A patent/SI2425825T1/en unknown
- 2003-04-04 HU HUE11177520A patent/HUE031668T2/en unknown
- 2003-04-04 AP APAP/P/2004/003137A patent/AP2043A/en active
- 2003-04-04 MX MXPA04009713A patent/MXPA04009713A/en active IP Right Grant
- 2003-04-04 DE DE60325567T patent/DE60325567D1/en not_active Expired - Lifetime
- 2003-04-04 ES ES11177518.5T patent/ES2627300T3/en not_active Expired - Lifetime
- 2003-04-04 EP EP10180498A patent/EP2316429A1/en not_active Withdrawn
- 2003-04-04 DK DK03720424.5T patent/DK1492505T3/en active
- 2003-04-04 EP EP11177513A patent/EP2425823A1/en not_active Withdrawn
- 2003-04-04 SI SI200332440T patent/SI1492505T1/en unknown
- 2003-04-04 DE DE17154462.0T patent/DE17154462T1/en active Pending
- 2003-04-04 EP EP03720424.5A patent/EP1492505B1/en not_active Revoked
- 2003-04-04 ES ES17169621T patent/ES2733044T1/en active Pending
- 2003-04-04 PT PT111775201T patent/PT2425825T/en unknown
- 2003-04-04 CN CN038077965A patent/CN1646102B/en not_active Expired - Lifetime
- 2003-04-04 EP EP20100176720 patent/EP2319496A1/en not_active Withdrawn
- 2003-04-04 CA CA002478523A patent/CA2478523A1/en not_active Abandoned
- 2003-04-04 DK DK11177518.5T patent/DK2425821T5/en active
- 2003-04-04 CA CA2478515A patent/CA2478515C/en not_active Expired - Lifetime
- 2003-04-04 AU AU2003224040A patent/AU2003224040B2/en not_active Expired
- 2003-04-04 DE DE20308437U patent/DE20308437U1/en not_active Expired - Lifetime
- 2003-04-04 BR BRPI0309544A patent/BRPI0309544B8/en not_active IP Right Cessation
- 2003-04-04 EP EP17169621.4A patent/EP3326618A1/en not_active Withdrawn
- 2003-04-04 LT LTEP11177520.1T patent/LT2425825T/en unknown
- 2003-04-04 EP EP11177520.1A patent/EP2425825B9/en not_active Revoked
- 2003-04-04 KR KR10-2004-7015828A patent/KR20040098050A/en not_active Application Discontinuation
- 2003-04-04 RU RU2004130845/15A patent/RU2297225C2/en active
- 2003-04-04 SI SI200331518T patent/SI1492506T1/en unknown
- 2003-04-04 MX MXPA04009714A patent/MXPA04009714A/en active IP Right Grant
- 2003-04-04 EP EP10180496A patent/EP2316428A1/en not_active Withdrawn
- 2003-04-04 EP EP05020579A patent/EP1639996A1/en not_active Withdrawn
- 2003-04-04 IL IL16399003A patent/IL163990A0/en unknown
- 2003-04-04 TW TW095133492A patent/TWI345973B/en not_active IP Right Cessation
- 2003-04-04 ES ES11177516.9T patent/ES2627298T3/en not_active Expired - Lifetime
- 2003-04-07 AR ARP030101200A patent/AR039378A1/en not_active Application Discontinuation
- 2003-04-07 AR ARP030101201A patent/AR039379A1/en not_active Application Discontinuation
-
2004
- 2004-09-09 IL IL163990A patent/IL163990A/en active IP Right Grant
- 2004-09-09 IL IL16398904A patent/IL163989A0/en unknown
- 2004-09-10 ZA ZA2004/07267A patent/ZA200407267B/en unknown
- 2004-09-13 ZA ZA2004/07317A patent/ZA200407317B/en unknown
- 2004-09-23 CO CO04094961A patent/CO5611100A2/en not_active Application Discontinuation
- 2004-09-24 CO CO04095278A patent/CO5611093A2/en not_active Application Discontinuation
- 2004-10-04 TN TNP2004000192A patent/TNSN04192A1/en unknown
- 2004-11-03 MA MA27928A patent/MA27249A1/en unknown
- 2004-11-03 MA MA27929A patent/MA27116A1/en unknown
-
2005
- 2005-06-15 HK HK05105024.4A patent/HK1072366A1/en not_active IP Right Cessation
- 2005-06-15 HK HK05105025.3A patent/HK1072367A1/en not_active IP Right Cessation
- 2005-06-15 HK HK12107145.5A patent/HK1166463A1/en not_active IP Right Cessation
-
2006
- 2006-08-08 RU RU2006128796/15A patent/RU2342935C2/en active
-
2007
- 2007-04-23 IL IL182742A patent/IL182742A0/en unknown
- 2007-08-17 FI FI20070322U patent/FI7846U1/en not_active IP Right Cessation
- 2007-09-18 DK DK200700243U patent/DK200700243U3/en not_active IP Right Cessation
-
2009
- 2009-03-13 JP JP2009061144A patent/JP5107954B2/en not_active Expired - Lifetime
- 2009-03-23 CY CY20091100346T patent/CY1108914T1/en unknown
- 2009-08-27 IL IL200621A patent/IL200621A/en active IP Right Grant
-
2010
- 2010-04-06 JP JP2010088165A patent/JP5932209B2/en not_active Expired - Lifetime
-
2011
- 2011-09-30 US US13/251,172 patent/US20120108621A1/en not_active Abandoned
-
2012
- 2012-01-11 US US13/348,617 patent/US8846090B2/en not_active Expired - Lifetime
-
2013
- 2013-04-15 AR ARP130101201A patent/AR090677A2/en not_active Application Discontinuation
- 2013-10-18 US US14/058,108 patent/US8846091B2/en not_active Expired - Lifetime
- 2013-10-18 US US14/058,068 patent/US20140045877A1/en not_active Abandoned
-
2014
- 2014-03-04 JP JP2014041261A patent/JP2014129397A/en active Pending
- 2014-06-16 US US14/305,785 patent/US9555000B2/en not_active Expired - Lifetime
- 2014-09-17 US US14/489,452 patent/US9655855B2/en not_active Expired - Lifetime
-
2015
- 2015-08-25 CY CY20151100735T patent/CY1116640T1/en unknown
-
2017
- 2017-01-05 US US15/399,487 patent/US9907793B2/en not_active Expired - Lifetime
- 2017-02-07 CY CY20171100165T patent/CY1118921T1/en unknown
- 2017-04-28 US US15/582,119 patent/US20170231978A1/en not_active Abandoned
- 2017-06-22 CY CY20171100665T patent/CY1119120T1/en unknown
- 2017-06-28 CY CY20171100683T patent/CY1119168T1/en unknown
-
2018
- 2018-01-26 US US15/881,459 patent/US10420762B2/en not_active Expired - Lifetime
- 2018-05-03 HK HK18105703.7A patent/HK1246176A1/en unknown
- 2018-06-25 PH PH12018000176A patent/PH12018000176A1/en unknown
- 2018-09-11 HK HK18111654.4A patent/HK1254279A1/en unknown
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8936808B1 (en) | 1997-12-22 | 2015-01-20 | Purdue Pharma L.P. | Opioid agonist/opioid antagonist/acetaminophen combinations |
US8673355B2 (en) | 1997-12-22 | 2014-03-18 | Purdue Pharma L.P. | Opioid agonist/antagonist combinations |
US8822487B2 (en) | 1997-12-22 | 2014-09-02 | Purdue Pharma L.P. | Opioid agonist/opioid antagonist/acetaminophen combinations |
US9474750B2 (en) | 1997-12-22 | 2016-10-25 | Purdue Pharma L.P. | Opioid agonist/opioid antagonist/acetaminophen combinations |
US9205082B2 (en) | 1997-12-22 | 2015-12-08 | Purdue Pharma L.P. | Opioid agonist/antagonist combinations |
US8932630B1 (en) | 1997-12-22 | 2015-01-13 | Purdue Pharma L.P | Opioid agonist/antagonist combinations |
US9161937B2 (en) | 2001-05-11 | 2015-10-20 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9345701B1 (en) | 2001-05-11 | 2016-05-24 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9056051B2 (en) | 2001-05-11 | 2015-06-16 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9084729B2 (en) | 2001-05-11 | 2015-07-21 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US8969369B2 (en) | 2001-05-11 | 2015-03-03 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9168252B2 (en) | 2001-05-11 | 2015-10-27 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9480685B2 (en) | 2001-05-11 | 2016-11-01 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9358230B1 (en) | 2001-05-11 | 2016-06-07 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9283216B2 (en) | 2001-05-11 | 2016-03-15 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9283221B2 (en) | 2001-05-11 | 2016-03-15 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9511066B2 (en) | 2001-05-11 | 2016-12-06 | Purdue Pharma L.P. | Abuse-resistant controlled-release opioid dosage form |
US9555000B2 (en) | 2002-04-05 | 2017-01-31 | Purdue Pharma L.P. | Pharmaceutical preparation containing oxycodone and naloxone |
US8846090B2 (en) | 2002-04-05 | 2014-09-30 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
US8846091B2 (en) | 2002-04-05 | 2014-09-30 | Euro-Celtique S.A. | Matrix for sustained, invariant and independent release of active compounds |
US8518925B2 (en) | 2004-06-08 | 2013-08-27 | Euro-Celtique S.A. | Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) |
US9271940B2 (en) | 2009-03-10 | 2016-03-01 | Purdue Pharma L.P. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10420762B2 (en) | Pharmaceutical preparation containing oxycodone and naloxone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20230404 |